<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35856662</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>18</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-6596</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><Issue>8</Issue><PubDate><Year>2022</Year><Month>Aug</Month><Day>16</Day></PubDate></JournalIssue><Title>Antimicrobial agents and chemotherapy</Title><ISOAbbreviation>Antimicrob Agents Chemother</ISOAbbreviation></Journal><ArticleTitle>OXA-48-Like &#x3b2;-Lactamases: Global Epidemiology, Treatment Options, and Development Pipeline.</ArticleTitle><Pagination><StartPage>e0021622</StartPage><MedlinePgn>e0021622</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e00216-22</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1128/aac.00216-22</ELocationID><Abstract><AbstractText>Modern medicine is threatened by the rising tide of antimicrobial resistance, especially among Gram-negative bacteria, where resistance to &#x3b2;-lactams is most often mediated by &#x3b2;-lactamases. The penicillin and cephalosporin ascendancies were, in their turn, ended by the proliferation of TEM penicillinases and CTX-M extended-spectrum &#x3b2;-lactamases. These class A &#x3b2;-lactamases have long been considered the most important. For carbapenems, however, the threat is increasingly from the insidious rise of a class D carbapenemase, OXA-48, and its close relatives. Over the past 20&#x2009;years, OXA-48 and "OXA-48-like" enzymes have proliferated to become the most prevalent enterobacterial carbapenemases across much of Europe, Northern Africa, and the Middle East. OXA-48-like enzymes are notoriously difficult to detect because they often cause only low-level <i>in vitro</i> resistance to carbapenems, meaning that the true burden is likely underestimated. Despite this, they are associated with carbapenem treatment failures. A highly conserved incompatibility complex IncL plasmid scaffold often carries <i>bla</i><sub>OXA-48</sub> and may carry other antimicrobial resistance genes, leaving limited treatment options. High conjugation efficiency means that this plasmid is sometimes carried by multiple <i>Enterobacterales</i> in a single patient. Producers evade most &#x3b2;-lactam-&#x3b2;-lactamase inhibitor combinations, though promising agents have recently been licensed, notably ceftazidime-avibactam and cefiderocol. The molecular machinery enabling global spread, current treatment options, and the development pipeline of potential new therapies for <i>Enterobacterales</i> that produce OXA-48-like &#x3b2;-lactamases form the focus of this review.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Boyd</LastName><ForeName>Sara E</ForeName><Initials>SE</Initials><Identifier Source="ORCID">0000-0001-9935-5263</Identifier><AffiliationInfo><Affiliation>Antimicrobial Pharmacodynamics and Therapeutics, Department of Molecular and Clinical Pharmacology, University of Liverpoolgrid.10025.36, Liverpool, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute for Health Research, Health Protection Research Unit in Healthcare Associated Infection and Antimicrobial Resistance, Imperial College London, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chelsea and Westminster NHS Foundation Trust, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holmes</LastName><ForeName>Alison</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>National Institute for Health Research, Health Protection Research Unit in Healthcare Associated Infection and Antimicrobial Resistance, Imperial College London, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Antimicrobial Optimisation, Imperial College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peck</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Antimicrobial Pharmacodynamics and Therapeutics, Department of Molecular and Clinical Pharmacology, University of Liverpoolgrid.10025.36, Liverpool, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pharma Research &amp; Development (pRED), Roche Innovation Center, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Livermore</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Norwich Medical School, University of East Anglia, Norwich, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hope</LastName><ForeName>William</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0001-6187-878X</Identifier><AffiliationInfo><Affiliation>Antimicrobial Pharmacodynamics and Therapeutics, Department of Molecular and Clinical Pharmacology, University of Liverpoolgrid.10025.36, Liverpool, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/N025989/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/R016895/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Antimicrob Agents Chemother</MedlineTA><NlmUniqueID>0315061</NlmUniqueID><ISSNLinking>0066-4804</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015780">Carbapenems</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D065093">beta-Lactamase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.5.2.6</RegistryNumber><NameOfSubstance UI="D001618">beta-Lactamases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Antimicrob Agents Chemother. 2022 Oct 18;66(10):e0110022. doi: 10.1128/aac.01100-22.</RefSource><PMID Version="1">36094308</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015780" MajorTopicYN="N">Carbapenems</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004755" MajorTopicYN="N">Enterobacteriaceae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008826" MajorTopicYN="N">Microbial Sensitivity Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065093" MajorTopicYN="Y">beta-Lactamase Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001618" MajorTopicYN="Y">beta-Lactamases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">OXA-48</Keyword><Keyword MajorTopicYN="N">OXA-48 &#x3b2;-lactamase</Keyword><Keyword MajorTopicYN="N">beta-lactamases</Keyword><Keyword MajorTopicYN="N">drug development</Keyword><Keyword MajorTopicYN="N">epidemiology</Keyword><Keyword MajorTopicYN="N">pharmacology</Keyword><Keyword MajorTopicYN="N">treatment</Keyword></KeywordList><CoiStatement>The authors declare a conflict of interest. S.E.B. held research funding through an MRC RCUK/UKRI Innovation Fellowship (MR/R016895/1) and the North West MRC Scheme in Clinical Pharmacology (MR/N025989/1). She received research support from Roche Pharma. S.E.B. has consulted for/received speaker fees for Sumitovant and Shionogi. A.H. co-supervises a PhD part funded by Shionogi in an industrial partnership doctoral training programme and has received consultation fees from bioM&#xe9;rieux. A.H. is supported by the National Institute for Health Research (NIHR) Health Protection Research Unit (HPRU) in Healthcare Associated Infections and Antimicrobial Resistance at Imperial College London in partnership with the UK Health Security Agency (previously PHE), in collaboration with, Imperial Healthcare Partners, University of Cambridge and University of Warwick. R.P. is an employee of F Hoffmann la Roche and holds stock and options amounting to &lt;10% of the total portfolio value. He is also a consultant to Insight-Rx. D.M.L.: Advisory Boards or ad hoc consultancy Accelerate, Antabio, Centauri, GenPax, Meiji, Menarini, Mutabilis, Nordic, Paion, ParaGraf, ParaPharm, Pfizer, QPEX, Shionogi, Sumitovant, Summit, T.A.Z., VenatoRx, Wockhardt, Zambon, Paid lectures - bioM&#xe9;rieux, GSK, Hikma, Merck/MSD, Menarini, Nordic, Pfizer, and Shionogi. Relevant shareholdings - Dechra, GSK, Merck and Perkinelmer, amounting to less than 10% of portfolio value. Share options - T.A.Z. and GenPax. He also has nominated holdings in Arecor, Avacta, Diaceutics, Creo Medical, Destiny Pharma Evgen, Genedrive, Poolbeg, Renalytics AI and Trellus (all with research/products pertinent to medicines or diagnostics) through Enterprise Investment Schemes but has no authority to trade these shares directly. W.H. holds or has recently held research grants with F2G, Astellas Pharma, Spero Therapeutics, Antabio, Allecra, Bugworks, and NAEJA-RGM. He holds awards from the Medical Research Council, National Institute of Health Research, FDA and the European Commission. W.H. has received personal fees in his capacity as a Consultant for F2G, Amplyx, Auspherix, Spero Therapeutics, VenatoRx, Pfizer and BLC/TAZ.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>20</Day><Hour>9</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>1</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35856662</ArticleId><ArticleId IdType="pmc">PMC9380527</ArticleId><ArticleId IdType="doi">10.1128/aac.00216-22</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Murray CJ, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G, Gray A, Han C, Bisignano C, Rao P, Wool E, Johnson SC, Browne AJ, Chipeta MG, Fell F, Hackett S, Haines-Woodhouse G, Kashef Hamadani BH, Kumaran EAP, McManigal B, Agarwal R, Akech S, Albertson S, Amuasi J, Andrews J, Aravkin A, Ashley E, Bailey F, Baker S, Basnyat B, Bekker A, Bender R, Bethou A, Bielicki J, Boonkasidecha S, Bukosia J, Carvalheiro C, Casta&#xf1;eda-Orjuela C, Chansamouth V, Chaurasia S, Chiurchi&#xf9; S, Chowdhury F, Cook AJ, Cooper B, Cressey TR, Criollo-Mora E, Cunningham M, Darboe S, Day NPJ, De Luca M, Dokova K, et al.. 2022. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 399:629&#x2013;655. 10.1016/S0140-6736(21)02724-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)02724-0</ArticleId><ArticleId IdType="pmc">PMC8841637</ArticleId><ArticleId IdType="pubmed">35065702</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivera&#x2010;Izquierdo M, L&#xe1;inez&#x2010;Ramos&#x2010;Bossini AJ, Rivera&#x2010;Izquierdo C, L&#xf3;pez&#x2010;G&#xf3;mez J, Fern&#xe1;ndez&#x2010;Mart&#xed;nez NF, Redruello&#x2010;Guerrero P, Mart&#xed;n&#x2010;Delosreyes LM, Mart&#xed;nez&#x2010;Ruiz V, Moreno&#x2010;Rold&#xe1;n E, Jim&#xe9;nez&#x2010;Mej&#xed;as E. 2021. OXA-48 carbapenemase-producing Enterobacterales in Spanish hospitals: an updated comprehensive review on a rising antimicrobial resistance. Antibiotics 10:89. 10.3390/antibiotics10010089.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antibiotics10010089</ArticleId><ArticleId IdType="pmc">PMC7832331</ArticleId><ArticleId IdType="pubmed">33477731</ArticleId></ArticleIdList></Reference><Reference><Citation>Vatansever C, Menekse S, Dogan O, Gucer LS, Ozer B, Ergonul O, Can F. 2020. Co-existence of OXA-48 and NDM-1 in colistin resistant Pseudomonas aeruginosa ST235. Emerg Microbes Infect 9:152&#x2013;154. 10.1080/22221751.2020.1713025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2020.1713025</ArticleId><ArticleId IdType="pmc">PMC7006663</ArticleId><ArticleId IdType="pubmed">31964275</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarafdar F, Jafari B, Azimi T. 2020. Evaluating the antimicrobial resistance patterns and molecular frequency of blaoxa-48 and blaGES-2 genes in Pseudomonas aeruginosa and Acinetobacter baumannii strains isolated from burn wound infection in Tehran, Iran. New Microbes New Infect 37:100686. 10.1016/j.nmni.2020.100686.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nmni.2020.100686</ArticleId><ArticleId IdType="pmc">PMC7394744</ArticleId><ArticleId IdType="pubmed">32774866</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuzon G, Naas T, Lesenne A, Benhamou M, Nordmann P. 2010. Plasmid-mediated carbapenem-hydrolysing OXA-48 &#x3b2;-lactamase in Klebsiella pneumoniae from Tunisia. Int J Antimicrob Agents 36:91&#x2013;93. 10.1016/j.ijantimicag.2010.02.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2010.02.014</ArticleId><ArticleId IdType="pubmed">20356714</ArticleId></ArticleIdList></Reference><Reference><Citation>Adler A, Shklyar M, Schwaber MJ, Navon-Venezia S, Dhaher Y, Edgar R, Solter E, Benenson S, Masarwa S, Carmeli Y. 2011. Introduction of OXA-48-producing Enterobacteriaceae to Israeli hospitals by medical tourism. J Antimicrob Chemother 66:2763&#x2013;2766. 10.1093/jac/dkr382.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkr382</ArticleId><ArticleId IdType="pubmed">22191089</ArticleId></ArticleIdList></Reference><Reference><Citation>Dautzenberg MJ, Ossewaarde JM, de Kraker ME, van der Zee A, van Burgh S, de Greeff SC, Bijlmer HA, Grundmann H, Cohen Stuart JW, Fluit AC, Troelstra A, Bonten MJ. 2014. Successful control of a hospital-wide outbreak of OXA-48 producing Enterobacteriaceae in the Netherlands, 2009 to 2011. Euro Surveill 19:20723. 10.2807/1560-7917.ES2014.19.9.20723.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES2014.19.9.20723</ArticleId><ArticleId IdType="pubmed">24626209</ArticleId></ArticleIdList></Reference><Reference><Citation>Howard JC, Anderson T, Creighton J, Freeman JT. 2018. Geographical and temporal clustering of OXA-48-producing Escherichia coli ST410 causing community-onset urinary tract infection in Christchurch, New Zealand. J Antimicrob Chemother 73:2900&#x2013;2901. 10.1093/jac/dky269.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dky269</ArticleId><ArticleId IdType="pubmed">29982524</ArticleId></ArticleIdList></Reference><Reference><Citation>Espedido BA, Steen JA, Ziochos H, Grimmond SM, Cooper MA, Gosbell IB, van Hal SJ, Jensen SO. 2013. Whole genome sequence analysis of the first Australian OXA-48-producing outbreak-associated Klebsiella pneumoniae isolates: the resistome and in vivo evolution. PLoS One 8:e59920. 10.1371/journal.pone.0059920.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0059920</ArticleId><ArticleId IdType="pmc">PMC3612081</ArticleId><ArticleId IdType="pubmed">23555831</ArticleId></ArticleIdList></Reference><Reference><Citation>Gharbi M, Moore LSP, Gilchrist M, Thomas CP, Bamford K, Brannigan ET, Holmes AH. 2015. Forecasting carbapenem resistance from antimicrobial consumption surveillance: lessons learnt from an OXA-48-producing Klebsiella pneumoniae outbreak in a West London renal unit. Int J Antimicrob Agents 46:150&#x2013;156. 10.1016/j.ijantimicag.2015.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2015.03.005</ArticleId><ArticleId IdType="pmc">PMC4526541</ArticleId><ArticleId IdType="pubmed">25979640</ArticleId></ArticleIdList></Reference><Reference><Citation>Brink AJ, Coetzee J, Corcoran C, Clay CG, Hari-Makkan D, Jacobson RK, Richards GA, Feldman C, Nutt L, Van Greune J, Deetlefs JD, Swart K, Devenish L, Poirel L, Nordmann P. 2013. Emergence of OXA-48 and OXA-181 carbapenemases among Enterobacteriaceae in South Africa and evidence of in vivo selection of colistin resistance as a consequence of selective decontamination of the gastrointestinal tract. J Clin Microbiol 51:369&#x2013;372. 10.1128/JCM.02234-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.02234-12</ArticleId><ArticleId IdType="pmc">PMC3536210</ArticleId><ArticleId IdType="pubmed">23152549</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L, An J, Ma Y, Ye L, Luo Y, Tao C, Yang J. 2016. Nosocomial outbreak of OXA-48-producing Klebsiella pneumoniae in a Chinese hospital: clonal transmission of ST147 and ST383. PLoS One 11:e0160754. 10.1371/journal.pone.0160754.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0160754</ArticleId><ArticleId IdType="pmc">PMC4973971</ArticleId><ArticleId IdType="pubmed">27490695</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitout JDD, Peirano G, Kock MM, Strydom KA, Matsumura Y. 2019. The global ascendency of OXA-48-type carbapenemases. Clin Microbiol Rev 33:e00102-19. 10.1128/CMR.00102-19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.00102-19</ArticleId><ArticleId IdType="pmc">PMC6860007</ArticleId><ArticleId IdType="pubmed">31722889</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart A, Harris P, Henderson A, Paterson D. 2018. Treatment of infections by OXA-48-producing Enterobacteriaceae. Antimicrob Agents Chemother 62:e01195-18. 10.1128/AAC.01195-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01195-18</ArticleId><ArticleId IdType="pmc">PMC6201068</ArticleId><ArticleId IdType="pubmed">30104282</ArticleId></ArticleIdList></Reference><Reference><Citation>Walther-Rasmussen J, H&#xf8;iby N. 2006. OXA-type carbapenemases. J Antimicrob Chemother 57:373&#x2013;383. 10.1093/jac/dki482.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dki482</ArticleId><ArticleId IdType="pubmed">16446375</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambler RP. 1980. The structure of &#x3b2;-lactamases. Philos Trans R Soc Lond B Biol Sci 289:321&#x2013;331. 10.1098/rstb.1980.0049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rstb.1980.0049</ArticleId><ArticleId IdType="pubmed">6109327</ArticleId></ArticleIdList></Reference><Reference><Citation>Naas T, Nordmann P. 1999. OXA-type &#x3b2;-lactamases. Curr Pharm Des 5:865&#x2013;879.</Citation><ArticleIdList><ArticleId IdType="pubmed">10539993</ArticleId></ArticleIdList></Reference><Reference><Citation>Bush K, Jacoby GA. 2010. Updated functional classification of &#x3b2;-lactamases. Antimicrob Agents Chemother 54:969&#x2013;976. 10.1128/AAC.01009-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01009-09</ArticleId><ArticleId IdType="pmc">PMC2825993</ArticleId><ArticleId IdType="pubmed">19995920</ArticleId></ArticleIdList></Reference><Reference><Citation>Poirel L, Naas T, Nordmann P. 2010. Diversity, epidemiology, and genetics of class D &#x3b2;-lactamases. Antimicrob Agents Chemother 54:24&#x2013;38. 10.1128/AAC.01512-08.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01512-08</ArticleId><ArticleId IdType="pmc">PMC2798486</ArticleId><ArticleId IdType="pubmed">19721065</ArticleId></ArticleIdList></Reference><Reference><Citation>Poirel L, Figueiredo S, Cattoir V, Carattoli A, Nordmann P. 2008. Acinetobacter radioresistens as a silent source of carbapenem resistance for Acinetobacter spp. Antimicrob Agents Chemother 52:1252&#x2013;1256. 10.1128/AAC.01304-07.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01304-07</ArticleId><ArticleId IdType="pmc">PMC2292503</ArticleId><ArticleId IdType="pubmed">18195058</ArticleId></ArticleIdList></Reference><Reference><Citation>Mairi A, Pantel A, Sotto A, Lavigne JP, Touati A. 2018. OXA-48-like carbapenemases producing Enterobacteriaceae in different niches. Eur J Clin Microbiol Infect Dis 37:587&#x2013;604. 10.1007/s10096-017-3112-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10096-017-3112-7</ArticleId><ArticleId IdType="pubmed">28990132</ArticleId></ArticleIdList></Reference><Reference><Citation>Potron A, Nordmann P, Lafeuille E, Al Maskari Z, Al Rashdi F, Poirel L. 2011. Characterization of OXA-181, a carbapenem-hydrolyzing class D &#x3b2;-lactamase from Klebsiella pneumoniae. Antimicrob Agents Chemother 55:4896&#x2013;4899. 10.1128/AAC.00481-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00481-11</ArticleId><ArticleId IdType="pmc">PMC3186949</ArticleId><ArticleId IdType="pubmed">21768505</ArticleId></ArticleIdList></Reference><Reference><Citation>Potron A, Rondinaud E, Poirel L, Belmonte O, Boyer S, Camiade S, Nordmann P. 2013. Genetic and biochemical characterisation of OXA-232, a carbapenem-hydrolysing class D &#x3b2;-lactamase from Enterobacteriaceae. Int J Antimicrob Agents 41:325&#x2013;329. 10.1016/j.ijantimicag.2012.11.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2012.11.007</ArticleId><ArticleId IdType="pubmed">23305656</ArticleId></ArticleIdList></Reference><Reference><Citation>Potron A, Nordmann P, Poirel L. 2013. Characterization of OXA-204, a carbapenem-hydrolyzing class D &#x3b2;-lactamase from Klebsiella pneumoniae. Antimicrob Agents Chemother 57:633&#x2013;636. 10.1128/AAC.01034-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01034-12</ArticleId><ArticleId IdType="pmc">PMC3535949</ArticleId><ArticleId IdType="pubmed">23114766</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasap M, Torol S, Kolayli F, Dundar D, Vahaboglu H. 2013. OXA-162, a novel variant of OXA-48 displays extended hydrolytic activity towards imipenem, meropenem and doripenem. J Enzyme Inhib Med Chem 28:990&#x2013;996. 10.3109/14756366.2012.702343.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/14756366.2012.702343</ArticleId><ArticleId IdType="pubmed">22845331</ArticleId></ArticleIdList></Reference><Reference><Citation>Poirel L, Castanheira M, Carr&#xeb;r A, Rodriguez CP, Jones RN, Smayevsky J, Nordmann P. 2011. OXA-163, an OXA-48-related class D &#x3b2;-lactamase with extended activity toward expanded-spectrum cephalosporins. Antimicrob Agents Chemother 55:2546&#x2013;2551. 10.1128/AAC.00022-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00022-11</ArticleId><ArticleId IdType="pmc">PMC3101449</ArticleId><ArticleId IdType="pubmed">21422200</ArticleId></ArticleIdList></Reference><Reference><Citation>Oteo J, Hern&#xe1;ndez JM, Espasa M, Fleites A, S&#xe1;ez D, Bautista V, P&#xe9;rez-V&#xe1;zquez M, Fern&#xe1;ndez-Garc&#xed;a MD, Delgado-Iribarren A, S&#xe1;nchez-Romero I, Garc&#xed;a-Picazo L, Miguel MD, Sol&#xed;s S, Aznar E, Trujillo G, Mediavilla C, Fontanals D, Rojo S, Vindel A, Campos J. 2013. Emergence of OXA-48-producing Klebsiella pneumoniae and the novel carbapenemases OXA-244 and OXA-245 in Spain. J Antimicrob Chemother 68:317&#x2013;321. 10.1093/jac/dks383.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dks383</ArticleId><ArticleId IdType="pubmed">23034714</ArticleId></ArticleIdList></Reference><Reference><Citation>Sampaio JLM, Ribeiro VB, Campos JC, Rozales FP, Magagnin CM, Falci DR, Silva RCFD, Dalarosa MG, Luz DI, Vieira FJ, Antochevis LC, Barth AL, Zavascki AP. 2014. Detection of OXA-370, an OXA-48-related class D &#x3b2;-lactamase, in Enterobacter hormaechei from Brazil. Antimicrob Agents Chemother 58:3566&#x2013;3567. 10.1128/AAC.02510-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.02510-13</ArticleId><ArticleId IdType="pmc">PMC4068428</ArticleId><ArticleId IdType="pubmed">24709259</ArticleId></ArticleIdList></Reference><Reference><Citation>Dortet L, Oueslati S, Jeannot K, Tand&#xe9; D, Naas T, Nordmann P. 2015. Genetic and biochemical characterization of OXA-405, an OXA-48-type extended-spectrum &#x3b2;-lactamase without significant carbapenemase activity. Antimicrob Agents Chemother 59:3823&#x2013;3828. 10.1128/AAC.05058-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.05058-14</ArticleId><ArticleId IdType="pmc">PMC4468662</ArticleId><ArticleId IdType="pubmed">25870062</ArticleId></ArticleIdList></Reference><Reference><Citation>Oueslati S, Retailleau P, Marchini L, Dortet L, Bonnin RA, Iorga BI, Naas T. 2019. Biochemical and structural characterization of OXA-405, an OXA-48 variant with extended-spectrum &#x3b2;-lactamase activity. Microorganisms 8:24. 10.3390/microorganisms8010024.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms8010024</ArticleId><ArticleId IdType="pmc">PMC7022249</ArticleId><ArticleId IdType="pubmed">31877796</ArticleId></ArticleIdList></Reference><Reference><Citation>Strynadka NCJ, Paetzel M, Danel F, de Castro L, Mosimann SC, Page MGP. 2000. Crystal structure of the class D &#x3b2;-lactamase OXA-10. Nat Struct Biol 7:918&#x2013;925. 10.1038/79688.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/79688</ArticleId><ArticleId IdType="pubmed">11017203</ArticleId></ArticleIdList></Reference><Reference><Citation>Pernot L, Fr&#xe9;nois F, Rybkine T, L'Hermite G, Petrella S, Delettr&#xe9; J, Jarlier V, Collatz E, Sougakoff W. 2001. Crystal structures of the class D &#x3b2;-lactamase OXA-13 in the native form and in complex with meropenem. J Mol Biol 310:859&#x2013;874. 10.1006/jmbi.2001.4805.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/jmbi.2001.4805</ArticleId><ArticleId IdType="pubmed">11453693</ArticleId></ArticleIdList></Reference><Reference><Citation>Giuliani F, Docquier JD, Riccio ML, Pagani L, Rossolini GM. 2005. OXA-46, a new class D &#x3b2;-lactamase of narrow substrate specificity encoded by a blaVIM-1-containing integron from a Pseudomonas aeruginosa clinical isolate. Antimicrob Agents Chemother 49:1973&#x2013;1980. 10.1128/AAC.49.5.1973-1980.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.49.5.1973-1980.2005</ArticleId><ArticleId IdType="pmc">PMC1087641</ArticleId><ArticleId IdType="pubmed">15855521</ArticleId></ArticleIdList></Reference><Reference><Citation>Docquier J-D, Calderone V, De Luca F, Benvenuti M, Giuliani F, Bellucci L, Tafi A, Nordmann P, Botta M, Rossolini GM, Mangani S. 2009. Crystal structure of the OXA-48 &#x3b2;-lactamase reveals mechanistic diversity among class D carbapenemases. Chem Biol 16:540&#x2013;547. 10.1016/j.chembiol.2009.04.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chembiol.2009.04.010</ArticleId><ArticleId IdType="pubmed">19477418</ArticleId></ArticleIdList></Reference><Reference><Citation>Couture F, Lachapelle J, Levesque RC. 1992. Phylogeny of LCR-1 and OXA-5 with class A and class D &#x3b2;-lactamases. Mol Microbiol 6:1693&#x2013;1705. 10.1111/j.1365-2958.1992.tb00894.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2958.1992.tb00894.x</ArticleId><ArticleId IdType="pubmed">1495394</ArticleId></ArticleIdList></Reference><Reference><Citation>Maveyraud L, Golemi D, Kotra LP, Tranier S, Vakulenko S, Mobashery S, Samama JP. 2000. Insights into class D &#x3b2;-lactamases are revealed by the crystal structure of the OXA10 enzyme from Pseudomonas aeruginosa. Structure 8:1289&#x2013;1298. 10.1016/S0969-2126(00)00534-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0969-2126(00)00534-7</ArticleId><ArticleId IdType="pubmed">11188693</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith CA, Antunes NT, Stewart NK, Toth M, Kumarasiri M, Chang M, Mobashery S, Vakulenko SB. 2013. Structural basis for carbapenemase activity of the OXA-23 &#x3b2;-lactamase from Acinetobacter baumannii. Chem Biol 20:1107&#x2013;1115. 10.1016/j.chembiol.2013.07.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chembiol.2013.07.015</ArticleId><ArticleId IdType="pmc">PMC3888872</ArticleId><ArticleId IdType="pubmed">24012371</ArticleId></ArticleIdList></Reference><Reference><Citation>Santillana E, Beceiro A, Bou G, Romero A. 2007. Crystal structure of the carbapenemase OXA-24 reveals insights into the mechanism of carbapenem hydrolysis. Proc Natl Acad Sci USA 104:5354&#x2013;5359. 10.1073/pnas.0607557104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0607557104</ArticleId><ArticleId IdType="pmc">PMC1838445</ArticleId><ArticleId IdType="pubmed">17374723</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith CA, Antunes NT, Toth M, Vakulenko SB. 2014. Crystal structure of carbapenemase OXA-58 from Acinetobacter baumannii. Antimicrob Agents Chemother 58:2135&#x2013;2143. 10.1128/AAC.01983-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01983-13</ArticleId><ArticleId IdType="pmc">PMC4023756</ArticleId><ArticleId IdType="pubmed">24468777</ArticleId></ArticleIdList></Reference><Reference><Citation>Oueslati S, Nordmann P, Poirel L. 2015. Heterogeneous hydrolytic features for OXA-48-like &#x3b2;-lactamases. J Antimicrob Chemother 70:1059&#x2013;1063. 10.1093/jac/dku524.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dku524</ArticleId><ArticleId IdType="pubmed">25583748</ArticleId></ArticleIdList></Reference><Reference><Citation>Poirel L, H&#xe9;ritier C, Nordmann P. 2004. Chromosome-encoded Ambler class D &#x3b2;-lactamase of Shewanella oneidensis as a progenitor of carbapenem-hydrolyzing oxacillinase. Antimicrob Agents Chemother 48:348&#x2013;351. 10.1128/AAC.48.1.348-351.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.48.1.348-351.2004</ArticleId><ArticleId IdType="pmc">PMC310178</ArticleId><ArticleId IdType="pubmed">14693565</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirvonen VHA, Mulholland AJ, Spencer J, Van Der Kamp MW. 2020. Small changes in hydration determine cephalosporinase activity of OXA-48 &#x3b2;-lactamases. ACS Catal 10:6188&#x2013;6196. 10.1021/acscatal.0c00596.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acscatal.0c00596</ArticleId></ArticleIdList></Reference><Reference><Citation>Tac&#xe3;o M, Ara&#xfa;jo S, Vendas M, Alves A, Henriques I. 2018. Shewanella species as the origin of blaOXA-48 genes: insights into gene diversity, associated phenotypes and possible transfer mechanisms. Int J Antimicrob Agents 51:340&#x2013;348. 10.1016/j.ijantimicag.2017.05.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2017.05.014</ArticleId><ArticleId IdType="pubmed">28666748</ArticleId></ArticleIdList></Reference><Reference><Citation>Mataseje LF, Boyd DA, Fuller J, Haldane D, Hoang L, Lefebvre B, Melano RG, Poutanen S, Van Caeseele P, Mulvey MR. 2018. Characterization of OXA-48-like carbapenemase producers in Canada, 2011&#x2013;14. J Antimicrob Chemother 73:626&#x2013;633. 10.1093/jac/dkx462.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkx462</ArticleId><ArticleId IdType="pubmed">29272439</ArticleId></ArticleIdList></Reference><Reference><Citation>Morita Y, Pecora N, G&#xf6;ttig S, Hamprecht A, Sommer J, Willmann M, Brender C, Stelzer Y, Krause FF, Tsvetkov T, Wild F, Riedel-Christ S, Kutschenreuter J, Imirzalioglu C, Gonzaga A, N&#xfc;bel U. 2019. Pathogenicity of clinical OXA-48 isolates and impact of the OXA-48 IncL plasmid on virulence and bacterial fitness. Front Microbiol 10:2509. 10.3389/fmicb.2019.02509.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2019.02509</ArticleId><ArticleId IdType="pmc">PMC6838017</ArticleId><ArticleId IdType="pubmed">31736929</ArticleId></ArticleIdList></Reference><Reference><Citation>Carr&#xeb;r A, Poirel L, Yilmaz M, Akan &#xd6;A, Feriha C, Cuzon G, Matar G, Honderlick P, Nordmann P. 2010. Spread of OXA-48-encoding plasmid in Turkey and beyond. Antimicrob Agents Chemother 54:1369&#x2013;1373. 10.1128/AAC.01312-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01312-09</ArticleId><ArticleId IdType="pmc">PMC2825965</ArticleId><ArticleId IdType="pubmed">20086157</ArticleId></ArticleIdList></Reference><Reference><Citation>Potron A, Bernabeu S, Cuzon G, Ponti&#xe8;s V, Blanchard H, Seringe E, Naas T, Nordmann P, Dortet L. 2017. Analysis of OXA-204 carbapenemase-producing Enterobacteriaceae reveals possible endoscopy-associated transmission, France, 2012 to 2014. Euro Surveill 22:17-00048. 10.2807/1560-7917.ES.2017.22.49.17-00048.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2017.22.49.17-00048</ArticleId><ArticleId IdType="pmc">PMC5727592</ArticleId><ArticleId IdType="pubmed">29233256</ArticleId></ArticleIdList></Reference><Reference><Citation>Strydom KA, Chen L, Kock MM, Stoltz AC, Peirano G, Nobrega DB, Lowe M, Ehlers MM, Mbelle NM, Kreiswirth BN, Pitout JDD. 2020. Klebsiella pneumoniae ST307 with OXA-181: threat of a high-risk clone and promiscuous plasmid in a resource-constrained healthcare setting. J Antimicrob Chemother 75:896&#x2013;902. 10.1093/jac/dkz550.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkz550</ArticleId><ArticleId IdType="pmc">PMC7069492</ArticleId><ArticleId IdType="pubmed">31953941</ArticleId></ArticleIdList></Reference><Reference><Citation>Brilhante M, Menezes J, Belas A, Feudi C, Schwarz S, Pomba C, Perreten V. 2020. OXA-181-producing extraintestinal pathogenic Escherichia coli sequence type 410 isolated from a dog in Portugal. Antimicrob Agents Chemother 64:e02298-19. 10.1128/AAC.02298-19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.02298-19</ArticleId><ArticleId IdType="pmc">PMC7179305</ArticleId><ArticleId IdType="pubmed">31964797</ArticleId></ArticleIdList></Reference><Reference><Citation>Poirel L, H&#xe9;ritier C, Tol&#xfc;n V, Nordmann P. 2004. Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob Agents Chemother 48:15&#x2013;22. 10.1128/AAC.48.1.15-22.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.48.1.15-22.2004</ArticleId><ArticleId IdType="pmc">PMC310167</ArticleId><ArticleId IdType="pubmed">14693513</ArticleId></ArticleIdList></Reference><Reference><Citation>Naha S, Sands K, Mukherjee S, Saha B, Dutta S, Basu S. 2021. OXA-181-like carbapenemases in Klebsiella pneumoniae ST14, ST15, ST23, ST48, and ST231 from septicemic neonates: coexistence with NDM-5, resistome, transmissibility, and genome diversity. mSphere 6:e01156-20. 10.1128/mSphere.01156-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mSphere.01156-20</ArticleId><ArticleId IdType="pmc">PMC7845606</ArticleId><ArticleId IdType="pubmed">33441403</ArticleId></ArticleIdList></Reference><Reference><Citation>Carr&#xeb;r A, Poirel L, Eraksoy H, Cagatay AA, Badur S, Nordmann P. 2008. Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey. Antimicrob Agents Chemother 52:2950&#x2013;2954. 10.1128/AAC.01672-07.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01672-07</ArticleId><ArticleId IdType="pmc">PMC2493117</ArticleId><ArticleId IdType="pubmed">18519712</ArticleId></ArticleIdList></Reference><Reference><Citation>Aubert D, Naas T, H&#xe9;ritier C, Poirel L, Nordmann P. 2006. Functional characterization of IS1999, an IS4 family element involved in mobilization and expression of &#x3b2;-lactam resistance genes. J Bacteriol 188:6506&#x2013;6514. 10.1128/JB.00375-06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JB.00375-06</ArticleId><ArticleId IdType="pmc">PMC1595497</ArticleId><ArticleId IdType="pubmed">16952941</ArticleId></ArticleIdList></Reference><Reference><Citation>Potron A, Poirel L, Nordmann P. 2014. Derepressed transfer properties leading to the efficient spread of the plasmid encoding carbapenemase OXA-48. Antimicrob Agents Chemother 58:467&#x2013;471. 10.1128/AAC.01344-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01344-13</ArticleId><ArticleId IdType="pmc">PMC3910765</ArticleId><ArticleId IdType="pubmed">24189247</ArticleId></ArticleIdList></Reference><Reference><Citation>Poirel L, Bonnin RA, Nordmann P. 2012. Genetic features of the widespread plasmid coding for the carbapenemase OXA-48. Antimicrob Agents Chemother 56:559&#x2013;562. 10.1128/AAC.05289-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.05289-11</ArticleId><ArticleId IdType="pmc">PMC3256075</ArticleId><ArticleId IdType="pubmed">22083465</ArticleId></ArticleIdList></Reference><Reference><Citation>Giani T, Conte V, Di Pilato V, Aschbacher R, Weber C, Larcher C, Rossolini GM. 2012. Escherichia coli from Italy producing OXA-48 carbapenemase encoded by a novel Tn1999 transposon derivative. Antimicrob Agents Chemother 56:2211&#x2013;2213. 10.1128/AAC.00035-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00035-12</ArticleId><ArticleId IdType="pmc">PMC3318333</ArticleId><ArticleId IdType="pubmed">22290939</ArticleId></ArticleIdList></Reference><Reference><Citation>Skalova A, Chudejova K, Rotova V, Medvecky M, Studentova V, Chudackova E, Lavicka P, Bergerova T, Jakubu V, Zemlickova H, Papagiannitsis CC, Hrabak J. 2017. Molecular characterization of OXA-48-like-producing Enterobacteriaceae in the Czech Republic and evidence for horizontal transfer of pOXA-48-like plasmids. Antimicrob Agents Chemother 61:e01889-16. 10.1128/AAC.01889-16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01889-16</ArticleId><ArticleId IdType="pmc">PMC5278705</ArticleId><ArticleId IdType="pubmed">27855076</ArticleId></ArticleIdList></Reference><Reference><Citation>Hidalgo L, de Been M, Rogers MRC, Sch&#xfc;rch AC, Scharringa J, van der Zee A, Bonten MJM, Fluit AC. 2019. Sequence-based epidemiology of an OXA-48 plasmid during a hospital outbreak. Antimicrob Agents Chemother 63:e01204-19. 10.1128/AAC.01204-19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01204-19</ArticleId><ArticleId IdType="pmc">PMC6879230</ArticleId><ArticleId IdType="pubmed">31591122</ArticleId></ArticleIdList></Reference><Reference><Citation>Peirano G, Chen L, Nobrega D, Finn TJ, Kreiswirth BN, DeVinney R, Pitout JDD. 2022. Genomic epidemiology of global carbapenemase-producing Escherichia coli, 2015&#x2013;2017. Emerg Infect Dis 28:924&#x2013;931. 10.3201/eid2805.212535.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2805.212535</ArticleId><ArticleId IdType="pmc">PMC9045447</ArticleId><ArticleId IdType="pubmed">35451367</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaidullina E, Shelenkov A, Yanushevich Y, Mikhaylova Y, Shagin D, Alexandrova I, Ershova O, Akimkin V, Kozlov R, Edelstein M. 2020. Antimicrobial resistance and genomic characterization of OXA-48-and CTX-M-15-co-producing hypervirulent Klebsiella pneumoniae ST23 recovered from nosocomial outbreak. Antibiotics 9:862. 10.3390/antibiotics9120862.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antibiotics9120862</ArticleId><ArticleId IdType="pmc">PMC7761672</ArticleId><ArticleId IdType="pubmed">33287207</ArticleId></ArticleIdList></Reference><Reference><Citation>Pano-Pardo JR, Ruiz-Carrascoso G, Navarro-San Francisco C, Gomez-Gil R, Mora-Rillo M, Romero-Gomez MP, Fernandez-Romero N, Garcia-Rodriguez J, Perez-Blanco V, Moreno-Ramos F, Mingorance J. 2013. Infections caused by OXA-48-producing Klebsiella pneumoniae in a tertiary hospital in Spain in the setting of a prolonged, hospital-wide outbreak. J Antimicrob Chemother 68:89&#x2013;96. 10.1093/jac/dks364.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dks364</ArticleId><ArticleId IdType="pubmed">23045224</ArticleId></ArticleIdList></Reference><Reference><Citation>Findlay J, Hopkins KL, Loy R, Doumith M, Meunier D, Hill R, Pike R, Mustafa N, Livermore DM, Woodford N. 2017. OXA-48-like carbapenemases in the UK: an analysis of isolates and cases from 2007 to 2014. J Antimicrob Chemother 72:1340&#x2013;1349. 10.1093/jac/dkx012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkx012</ArticleId><ArticleId IdType="pubmed">28199647</ArticleId></ArticleIdList></Reference><Reference><Citation>European Centre for Disease Prevention and Control. 2021. Rapid risk assessment: increase in OXA-244 -producing Escherichia coli in the European Union/European Economic Area and the UK since 2013, first update. https://www.ecdc.europa.eu/en/publications-data/rapid-risk-assessment-increase-oxa-244-producing-escherichia-coli-eu-eea. Accessed 3 June 2022.</Citation></Reference><Reference><Citation>Isler B, &#xd6;zer B, &#xc7;&#x131;nar G, Aslan AT, Vatansever C, Falconer C, Dolap&#xe7;&#x131; &#x130;, &#x15e;im&#x15f;ek F, T&#xfc;lek N, Demirkaya H, Menek&#x15f;e &#x15e;, Akalin H, Balkan &#x130;&#x130;, Ayd&#x131;n M, Tigen ET, Demir SK, Kapmaz M, Keske &#x15e;, Do&#x11f;an &#xd6;, Arabac&#x131; &#xc7;, Ya&#x11f;c&#x131; S, Haz&#x131;rolan G, Bak&#x131;r VO, G&#xf6;nen M, Chatfield MD, Forde B, Salto&#x11f;lu N, Azap A, Azap &#xd6;, Akova M, Paterson DL, Can F, Erg&#xf6;n&#xfc;l &#xd6;. 2022. Characteristics and outcomes of carbapenemase harbouring carbapenem-resistant Klebsiella spp. bloodstream infections: a multicentre prospective cohort study in an OXA-48 endemic setting. Eur J Clin Microbiol Infect Dis 41:841&#x2013;847. 10.1007/s10096-022-04425-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10096-022-04425-4</ArticleId><ArticleId IdType="pubmed">35301623</ArticleId></ArticleIdList></Reference><Reference><Citation>Moubareck CA, Mouftah SF, P&#xe1;l T, Ghazawi A, Halat DH, Nabi A, AlSharhan MA, AlDeesi ZO, Peters CC, Celiloglu H, Sannegowda M, Sarkis DK, Sonnevend &#xc1;. 2018. Clonal emergence of Klebsiella pneumoniae ST14 co-producing OXA-48-type and NDM carbapenemases with high rate of colistin resistance in Dubai, United Arab Emirates. Int J Antimicrob Agents 52:90&#x2013;95. 10.1016/j.ijantimicag.2018.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2018.03.003</ArticleId><ArticleId IdType="pubmed">29530587</ArticleId></ArticleIdList></Reference><Reference><Citation>Mushtaq S, Garello P, Vickers A, Woodford N, Livermore DM. 2021. Activity of cefepime/zidebactam (WCK 5222) against &#x201c;problem&#x201d; antibiotic-resistant Gram-negative bacteria sent to a national reference laboratory. J Antimicrob Chemother 76:1511&#x2013;1522. 10.1093/jac/dkab067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkab067</ArticleId><ArticleId IdType="pubmed">33760082</ArticleId></ArticleIdList></Reference><Reference><Citation>Kidd JM, Livermore DM, Nicolau DP. 2020. The difficulties of identifying and treating Enterobacterales with OXA-48-like carbapenemases. Clin Microbiol Infect 26:401&#x2013;403. 10.1016/j.cmi.2019.12.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2019.12.006</ArticleId><ArticleId IdType="pubmed">31899334</ArticleId></ArticleIdList></Reference><Reference><Citation>Dabos L, Oueslati S, Bernabeu S, Bonnin RA, Dortet L, Naas T. 2022. To be or not to be an OXA-48 carbapenemase. Microorganisms 10:258. 10.3390/microorganisms10020258.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms10020258</ArticleId><ArticleId IdType="pmc">PMC8875484</ArticleId><ArticleId IdType="pubmed">35208713</ArticleId></ArticleIdList></Reference><Reference><Citation>Livermore DM, Nicolau DP, Hopkins KL, Meunier D. 2020. Carbapenem-resistant Enterobacterales, carbapenem resistant organisms, carbapenemase-producing Enterobacterales, and carbapenemase-producing organisms: terminology past its &#x201c;sell-by date&#x201d; in an era of new antibiotics and regional carbapenemase epidemiology. Clin Infect Dis 71:1776&#x2013;1782. 10.1093/cid/ciaa122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa122</ArticleId><ArticleId IdType="pubmed">32025698</ArticleId></ArticleIdList></Reference><Reference><Citation>Livermore DM, Meunier D, Hopkins KL, Doumith M, Hill R, Pike R, Staves P, Woodford N. 2018. Activity of ceftazidime/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015-16. J Antimicrob Chemother 73:648&#x2013;657. 10.1093/jac/dkx438.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkx438</ArticleId><ArticleId IdType="pubmed">29228202</ArticleId></ArticleIdList></Reference><Reference><Citation>EUCAST. 2022. Clinical breakpoints and dosing of antibiotics v.12.0. https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_12.0_Breakpoint_Tables.pdf. Accessed 3 May 2022.</Citation></Reference><Reference><Citation>Clinical and Laboratory Standards Institute. 2021. CLSI performance standards for antimicrobial susceptibility testing, 31st ed. M100-ED31. http://em100.edaptivedocs.net/Login.aspx?_ga=2.33444157.2034438934.1644156008-100107473.1644156008. Accessed 6 February 2022.</Citation></Reference><Reference><Citation>Fattouh R, Tijet N, McGeer A, Poutanen SM, Melano RG, Patel SN. 2015. What is the appropriate meropenem MIC for screening of carbapenemase-producing Enterobacteriaceae in low-prevalence settings? Antimicrob Agents Chemother 60:1556&#x2013;1559. 10.1128/AAC.02304-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.02304-15</ArticleId><ArticleId IdType="pmc">PMC4776007</ArticleId><ArticleId IdType="pubmed">26711746</ArticleId></ArticleIdList></Reference><Reference><Citation>Cant&#xf3;n R, Ak&#xf3;va M, Carmeli Y, Giske CG, Glupczynski Y, Gniadkowski M, Livermore DM, Miriagou V, Naas T, Rossolini GM, Samuelsen Seifert H, Woodford N, Nordmann P, Poirel L, Bogaerts P, Navon-Venezia S, Cornaglia G, European Network on Carbapenemases. 2012. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin Microbiol Infect 18:413&#x2013;431. 10.1111/j.1469-0691.2012.03821.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1469-0691.2012.03821.x</ArticleId><ArticleId IdType="pubmed">22507109</ArticleId></ArticleIdList></Reference><Reference><Citation>Castanheira M, Doyle TB, Collingsworth TD, Sader HS, Mendes RE. 2021. Increasing frequency of OXA-48-producing Enterobacterales worldwide and activity of ceftazidime/avibactam, meropenem/vaborbactam and comparators against these isolates. J Antimicrob Chemother 76:3125&#x2013;3134. 10.1093/jac/dkab306.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkab306</ArticleId><ArticleId IdType="pmc">PMC8598286</ArticleId><ArticleId IdType="pubmed">34459890</ArticleId></ArticleIdList></Reference><Reference><Citation>Otlu B, Yakupo&#x11f;ullari Y, G&#xfc;rsoy NC, Duman Y, Bayindir Y, Tekereko&#x11f;lu MS, Ersoy Y. 2018. Co-production of OXA-48 and NDM-1 carbapenemases in Providencia rettgeri: the first report. Mikrobiyol Bul 52:300&#x2013;307. 10.5578/mb.67153. (In Turkish.)</Citation><ArticleIdList><ArticleId IdType="doi">10.5578/mb.67153</ArticleId><ArticleId IdType="pubmed">30156516</ArticleId></ArticleIdList></Reference><Reference><Citation>Flach CF, Hutinel M, Razavi M, &#xc5;hr&#xe9;n C, Larsson DGJ. 2021. Monitoring of hospital sewage shows both promise and limitations as an early-warning system for carbapenemase-producing Enterobacterales in a low-prevalence setting. Water Res 200:117261. 10.1016/j.watres.2021.117261.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.watres.2021.117261</ArticleId><ArticleId IdType="pubmed">34082263</ArticleId></ArticleIdList></Reference><Reference><Citation>Campos-Madueno EI, Moser AI, Jost G, Maffioli C, Bodmer T, Perreten V, Endimiani A. 2022. Carbapenemase-producing Klebsiella pneumoniae strains in Switzerland: human and non-human settings may share high-risk clones. J Glob Antimicrob Resist 28:206&#x2013;215. 10.1016/j.jgar.2022.01.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jgar.2022.01.016</ArticleId><ArticleId IdType="pubmed">35085791</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitt K, Biggel M, Stephan R, Willi B. 2022. Massive spread of OXA-48 carbapenemase-producing Enterobacteriaceae in the environment of a Swiss companion animal clinic. Antibiotics 11:213. 10.3390/antibiotics11020213.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antibiotics11020213</ArticleId><ArticleId IdType="pmc">PMC8868282</ArticleId><ArticleId IdType="pubmed">35203816</ArticleId></ArticleIdList></Reference><Reference><Citation>Nigg A, Brilhante M, Dazio V, Cl&#xe9;ment M, Collaud A, Brawand SG, Willi B, Endimiani A, Schuller S, Perreten V. 2019. Shedding of OXA-181 carbapenemase-producing Escherichia coli from companion animals after hospitalisation in Switzerland: an outbreak in 2018. Euro Surveill 24:1900071. 10.2807/1560-7917.ES.2019.24.39.1900071.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2019.24.39.1900071</ArticleId><ArticleId IdType="pmc">PMC6774230</ArticleId><ArticleId IdType="pubmed">31576806</ArticleId></ArticleIdList></Reference><Reference><Citation>Lohr B, Pfeifer Y, Heudorf U, Rangger C, Norris DE, Hunfeld KP. 2018. High prevalence of multidrug-resistant bacteria in Libyan war casualties admitted to a tertiary care hospital, Germany. Microb Drug Resist 24:578&#x2013;584. 10.1089/mdr.2017.0141.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/mdr.2017.0141</ArticleId><ArticleId IdType="pubmed">29039717</ArticleId></ArticleIdList></Reference><Reference><Citation>Zorgani A, Ziglam H. 2013. Injured Libyan combatant patients: both vectors and victims of multiresistance bacteria? Libyan J Med 8:20325. 10.3402/ljm.v8i0.20325.</Citation><ArticleIdList><ArticleId IdType="doi">10.3402/ljm.v8i0.20325</ArticleId><ArticleId IdType="pmc">PMC3572213</ArticleId><ArticleId IdType="pubmed">23413373</ArticleId></ArticleIdList></Reference><Reference><Citation>Koole K, Ellerbroek PM, Lagendijk R, Leenen LPH, Ekkelenkamp MB. 2013. Colonization of Libyan civil war casualties with multidrug-resistant bacteria. Clin Microbiol Infect 19:E285&#x2013;E287. 10.1111/1469-0691.12135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1469-0691.12135</ArticleId><ArticleId IdType="pubmed">23413838</ArticleId></ArticleIdList></Reference><Reference><Citation>Albiger B, Glasner C, Struelens MJ, Grundmann H, Monnet DL, The European Survey of Carbapenemase-Producing Enterobacteriaceae (EuSCAPE) Working Group. 2015. Carbapenemase-producing Enterobacteriaceae in Europe: assessment by national experts from 38 countries, May 2015. Euro Surveill 20:30062. 10.2807/1560-7917.ES.2015.20.45.30062.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2015.20.45.30062</ArticleId><ArticleId IdType="pubmed">26675038</ArticleId></ArticleIdList></Reference><Reference><Citation>Seiffert SN, Perreten V, Johannes S, Droz S, Bodmer T, Endimiani A. 2014. OXA-48 carbapenemase-producing Salmonella enterica serovar Kentucky isolate of sequence type 198 in a patient transferred from Libya to Switzerland. Antimicrob Agents Chemother 58:2446&#x2013;2449. 10.1128/AAC.02417-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.02417-13</ArticleId><ArticleId IdType="pmc">PMC4023741</ArticleId><ArticleId IdType="pubmed">24468781</ArticleId></ArticleIdList></Reference><Reference><Citation>Moser AI, Campos-Madueno EI, Sendi P, Perreten V, Keller PM, Ramette A, Endimiani A. 2021. Repatriation of a patient with COVID-19 contributed to the importation of an emerging carbapenemase producer. J Glob Antimicrob Resist 27:267&#x2013;272. 10.1016/j.jgar.2021.10.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jgar.2021.10.012</ArticleId><ArticleId IdType="pmc">PMC8552635</ArticleId><ArticleId IdType="pubmed">34718203</ArticleId></ArticleIdList></Reference><Reference><Citation>Logan LK, Weinstein RA. 2017. The epidemiology of carbapenem-resistant Enterobacteriaceae: the impact and evolution of a global menace. J Infect Dis 215:S28&#x2013;S36. 10.1093/infdis/jiw282.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiw282</ArticleId><ArticleId IdType="pmc">PMC5853342</ArticleId><ArticleId IdType="pubmed">28375512</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuzon G, Naas T, Bogaerts P, Glupczynski Y, Huang TD, Nordmann P. 2008. Plasmid-encoded carbapenem-hydrolyzing &#x3b2;-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium. Antimicrob Agents Chemother 52:3463&#x2013;3464. 10.1128/AAC.00543-08.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00543-08</ArticleId><ArticleId IdType="pmc">PMC2533501</ArticleId><ArticleId IdType="pubmed">18644970</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuzon G, Ouanich J, Gondret R, Naas T, Nordmann P. 2011. Outbreak of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in France. Antimicrob Agents Chemother 55:2420&#x2013;2423. 10.1128/AAC.01452-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01452-10</ArticleId><ArticleId IdType="pmc">PMC3088266</ArticleId><ArticleId IdType="pubmed">21343451</ArticleId></ArticleIdList></Reference><Reference><Citation>Gauthier L, Dortet L, Cotellon G, Creton E, Cuzon G, Ponties V, Bonnin RA, Naas T. 2018. Diversity of carbapenemase-producing Escherichia coli isolates in France in 2012-2013. Antimicrob Agents Chemother 62:e00266-18. 10.1128/AAC.00266-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00266-18</ArticleId><ArticleId IdType="pmc">PMC6105832</ArticleId><ArticleId IdType="pubmed">29866863</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xe1;zaro-Perona F, Dahdouh E, Sotillo A, P&#xe9;rez-Blanco V, Villa J, Viedma E, Ruiz-Carrascoso G, Mingorance J. 2022. Dissemination of a single ST11 clone of OXA-48-producing Klebsiella pneumoniae within a large polyclonal hospital outbreak determined by genomic sequencing. Microb Genom 8:808. 10.1099/mgen.0.000808.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/mgen.0.000808</ArticleId><ArticleId IdType="pmc">PMC9453077</ArticleId><ArticleId IdType="pubmed">35394416</ArticleId></ArticleIdList></Reference><Reference><Citation>Miro E, Rossen JWA, Chlebowicz MA, Harmsen D, Brisse S, Passet V, Navarro F, Friedrich AW, Garc&#xed;a-Cobos S. 2020. Core/whole genome multilocus sequence typing and core genome SNP-based typing of OXA-48-producing Klebsiella pneumoniae clinical isolates from Spain Front Microbiol 10:2961. 10.3389/fmicb.2019.02961.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2019.02961</ArticleId><ArticleId IdType="pmc">PMC7005014</ArticleId><ArticleId IdType="pubmed">32082262</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayol A, Poirel L, Dortet L, Nordmann P. 2016. National survey of colistin resistance among carbapenemase-producing Enterobacteriaceae and outbreak caused by colistin-resistant OXA-48-producing Klebsiella pneumoniae, France, 2014. Euro Surveill 21:30339. 10.2807/1560-7917.ES.2016.21.37.30339.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2016.21.37.30339</ArticleId><ArticleId IdType="pmc">PMC5032854</ArticleId><ArticleId IdType="pubmed">27685838</ArticleId></ArticleIdList></Reference><Reference><Citation>Lerner A, Solter E, Rachi E, Adler A, Rechnitzer H, Miron D, Krupnick L, Sela S, Aga E, Ziv Y, Peretz A, Labay K, Rahav G, Geffen Y, Hussein K, Eluk O, Carmeli Y, Schwaber MJ. 2016. Detection and characterization of carbapenemase-producing Enterobacteriaceae in wounded Syrian patients admitted to hospitals in northern Israel. Eur J Clin Microbiol Infect Dis 35:149&#x2013;154. 10.1007/s10096-015-2520-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10096-015-2520-9</ArticleId><ArticleId IdType="pubmed">26581423</ArticleId></ArticleIdList></Reference><Reference><Citation>Kola A, Piening B, Pape UF, Veltzke-Schlieker W, Kaase M, Geffers C, Wiedenmann B, Gastmeier P. 2015. An outbreak of carbapenem-resistant OXA-48-producing Klebsiella pneumoniae associated to duodenoscopy. Antimicrob Resist Infect Control 4:8. 10.1186/s13756-015-0049-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13756-015-0049-4</ArticleId><ArticleId IdType="pmc">PMC4374528</ArticleId><ArticleId IdType="pubmed">25815166</ArticleId></ArticleIdList></Reference><Reference><Citation>Zurfluh K, N&#xfc;esch-Inderbinen MT, Poirel L, Nordmann P, H&#xe4;chler H, Stephan R. 2015. Emergence of Escherichia coli producing OXA-48 &#x3b2;-lactamase in the community in Switzerland. Antimicrob Resist Infect Control 4:9. 10.1186/s13756-015-0051-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13756-015-0051-x</ArticleId><ArticleId IdType="pmc">PMC4381362</ArticleId><ArticleId IdType="pubmed">25834728</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordmann P, Poirel L. 2014. The difficult-to-control spread of carbapenemase producers among Enterobacteriaceae worldwide. Clin Microbiol Infect 20:821&#x2013;830. 10.1111/1469-0691.12719.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1469-0691.12719</ArticleId><ArticleId IdType="pubmed">24930781</ArticleId></ArticleIdList></Reference><Reference><Citation>UK Health Security Agency. 2021. English surveillance programme for antimicrobial utilisation and resistance (ESPAUR) 2020&#x2013;2021. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1033851/espaur-report-2020-to-2021-16-Nov.pdf. Accessed 6 February 2022.</Citation></Reference><Reference><Citation>Falgenhauer L, Nordmann P, Imirzalioglu C, Yao Y, Falgenhauer J, Hauri AM, Heinm&#xfc;ller P, Chakraborty T. 2020. Cross-border emergence of clonal lineages of ST38 Escherichia coli producing the OXA-48-like carbapenemase OXA-244 in Germany and Switzerland. Int J Antimicrob Agents 56:106157. 10.1016/j.ijantimicag.2020.106157.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2020.106157</ArticleId><ArticleId IdType="pubmed">32919009</ArticleId></ArticleIdList></Reference><Reference><Citation>Masseron A, Poirel L, Falgenhauer L, Imirzalioglu C, Kessler J, Chakraborty T, Nordmann P. 2020. Ongoing dissemination of OXA-244 carbapenemase-producing Escherichia coli in Switzerland and their detection. Diagn Microbiol Infect Dis 97:115059. 10.1016/j.diagmicrobio.2020.115059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diagmicrobio.2020.115059</ArticleId><ArticleId IdType="pubmed">32387849</ArticleId></ArticleIdList></Reference><Reference><Citation>Lev AI, Astashkin EI, Kislichkina AA, Solovieva EV, Kombarova TI, Korobova OV, Ershova ON, Alexandrova IA, Malikov VE, Bogun AG, Borzilov AI, Volozhantsev NV, Svetoch EA, Fursova NK. 2018. Comparative analysis of Klebsiella pneumoniae strains isolated in 2012&#x2013;2016 that differ by antibiotic resistance genes and virulence genes profiles. Pathog Glob Health 112:142&#x2013;151. 10.1080/20477724.2018.1460949.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/20477724.2018.1460949</ArticleId><ArticleId IdType="pmc">PMC6056825</ArticleId><ArticleId IdType="pubmed">29708041</ArticleId></ArticleIdList></Reference><Reference><Citation>Volozhantsev NV, Kislichkina AA, Mukhina TN, Fursova NK. 2020. Draft genome sequences of clinical K1-type Klebsiella pneumoniae strains isolated in Russia. Microbiol Resour Announc 9:e01250-19. 10.1128/MRA.01250-19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MRA.01250-19</ArticleId><ArticleId IdType="pmc">PMC6940289</ArticleId><ArticleId IdType="pubmed">31896637</ArticleId></ArticleIdList></Reference><Reference><Citation>European Centre for Disease Prevention and Control. 2021. Emergence of hypervirulent Klebsiella pneumoniae ST23 carrying carbapenemase genes in EU/EEA countries. https://www.ecdc.europa.eu/sites/default/files/documents/Emergence-of-hypervirulent-Klebsiella-pneumoniae-ST23-carrying-carbapenemase-genes.pdf. Accessed 6 February 2022.</Citation></Reference><Reference><Citation>Blanc DS, Poirel L, Van Singer M, Greub G, Nordmann P. 2021. Hypervirulent Klebsiella pneumoniae ST23 producing OXA-48 in Switzerland. Int J Antimicrob Agents 58:106457. 10.1016/j.ijantimicag.2021.106457.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2021.106457</ArticleId><ArticleId IdType="pubmed">34699934</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Baloushi AE, P&#xe1;l T, Ghazawi A, Sonnevend A. 2018. Genetic support of carbapenemases in double carbapenemase producer Klebsiella pneumoniae isolated in the Arabian Peninsula. Acta Microbiol Immunol Hung 65:135&#x2013;150. 10.1556/030.65.2018.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1556/030.65.2018.005</ArticleId><ArticleId IdType="pubmed">29471690</ArticleId></ArticleIdList></Reference><Reference><Citation>Sa&#xef;dani M, Hammami S, Kammoun A, Slim A, Boutiba-Ben Boubaker I. 2012. Emergence of carbapenem-resistant OXA-48 carbapenemase-producing Enterobacteriaceae in Tunisia. J Med Microbiol 61:1746&#x2013;1749. 10.1099/jmm.0.045229-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/jmm.0.045229-0</ArticleId><ArticleId IdType="pubmed">22918869</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherif M, Palmieri M, Mirande C, El-Mahallawy H, Rashed HG, Abd-El-Reheem F, El-Manakhly AR, Abdel-Latif RAR, Aboulela AG, Saeed LY, Abdel-Rahman S, Elsayed E, van Belkum A, El-Kholy A. 2021. Whole-genome sequencing of Egyptian multidrug-resistant Klebsiella pneumoniae isolates: a multi-center pilot study. Eur J Clin Microbiol Infect Dis 40:1451&#x2013;1460. 10.1007/s10096-021-04177-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10096-021-04177-7</ArticleId><ArticleId IdType="pubmed">33559021</ArticleId></ArticleIdList></Reference><Reference><Citation>Poirel L, Potron A, Nordmann P. 2012. OXA-48-like carbapenemases: the phantom menace. J Antimicrob Chemother 67:1597&#x2013;1606. 10.1093/jac/dks121.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dks121</ArticleId><ArticleId IdType="pubmed">22499996</ArticleId></ArticleIdList></Reference><Reference><Citation>Lahlaoui H, Poirel L, Barguellil F, Moussa MB, Nordmann P. 2012. Carbapenem-hydrolyzing class D &#x3b2;-lactamase OXA-48 in Klebsiella pneumoniae isolates from Tunisia. Eur J Clin Microbiol Infect Dis 31:937&#x2013;939. 10.1007/s10096-011-1389-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10096-011-1389-5</ArticleId><ArticleId IdType="pubmed">21915739</ArticleId></ArticleIdList></Reference><Reference><Citation>Alp E, Per&#xe7;in D, Colako&#x11f;lu S, Durmaz S, K&#xfc;rkc&#xfc; CA, Ekincio&#x11f;lu P, G&#xfc;ne&#x15f; T. 2013. Molecular characterization of carbapenem-resistant Klebsiella pneumoniae in a tertiary university hospital in Turkey. J Hosp Infect 84:178&#x2013;180. 10.1016/j.jhin.2013.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhin.2013.03.002</ArticleId><ArticleId IdType="pubmed">23623803</ArticleId></ArticleIdList></Reference><Reference><Citation>Osman EA, El-Amin NI, Al-Hassan LL, Mukhtar M. 2021. Multi-clonal spread of Klebsiella pneumoniae across hospitals in Khartoum, Sudan. J Glob Antimicrob Resist 24:241&#x2013;245. 10.1016/j.jgar.2020.12.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jgar.2020.12.004</ArticleId><ArticleId IdType="pubmed">33373737</ArticleId></ArticleIdList></Reference><Reference><Citation>Moquet O, Bouchiat C, Kinana A, Seck A, Arouna O, Bercion R, Breurec S, Garin B. 2011. Class D OXA-48 carbapenemase in multidrug-resistant Enterobacteria, Senegal. Emerg Infect Dis 17:143&#x2013;144. 10.3201/eid1701.100244.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1701.100244</ArticleId><ArticleId IdType="pmc">PMC3204621</ArticleId><ArticleId IdType="pubmed">21192883</ArticleId></ArticleIdList></Reference><Reference><Citation>Osei Sekyere J, Reta MA. 2020. Genomic and resistance epidemiology of Gram-negative bacteria in Africa: a systematic review and phylogenomic analyses from a One Health perspective. mSystems 5:e00897-20. 10.1128/mSystems.00897-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mSystems.00897-20</ArticleId><ArticleId IdType="pmc">PMC7687029</ArticleId><ArticleId IdType="pubmed">33234606</ArticleId></ArticleIdList></Reference><Reference><Citation>Manenzhe RI, Zar HJ, Nicol MP, Kaba M. 2015. The spread of carbapenemase-producing bacteria in Africa: a systematic review. J Antimicrob Chemother 70:23&#x2013;40. 10.1093/jac/dku356.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dku356</ArticleId><ArticleId IdType="pmc">PMC5975721</ArticleId><ArticleId IdType="pubmed">25261423</ArticleId></ArticleIdList></Reference><Reference><Citation>Perovic O, Britz E, Chetty V, Singh-Moodley A. 2016. Molecular detection of carbapenemase-producing genes in referral Enterobacteriaceae in South Africa: a short report. S Afr Med J 106:975&#x2013;977. 10.7196/SAMJ.2016.v106i10.11300.</Citation><ArticleIdList><ArticleId IdType="doi">10.7196/SAMJ.2016.v106i10.11300</ArticleId><ArticleId IdType="pubmed">27725012</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowe M, Kock MM, Coetzee J, Hoosien E, Peirano G, Strydom KA, Ehlers MM, Mbelle NM, Shashkina E, Haslam DB, Dhawan P, Donnelly RJ, Chen L, Kreiswirth BN, Pitout JDD. 2019. Klebsiella pneumoniae ST307 with blaOXA-181, South Africa, 2014&#x2013;2016. Emerg Infect Dis 25:739&#x2013;747. 10.3201/eid2504.181482.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2504.181482</ArticleId><ArticleId IdType="pmc">PMC6433043</ArticleId><ArticleId IdType="pubmed">30882333</ArticleId></ArticleIdList></Reference><Reference><Citation>Touati A, Mairi A. 2020. Epidemiology of carbapenemase-producing Enterobacterales in the Middle East: a systematic review. Expert Rev Anti Infect Ther 18:241&#x2013;250. 10.1080/14787210.2020.1729126.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14787210.2020.1729126</ArticleId><ArticleId IdType="pubmed">32043905</ArticleId></ArticleIdList></Reference><Reference><Citation>Solgi H, Giske CG, Badmasti F, Aghamohammad S, Havaei SA, Sabeti S, Mostafavizadeh K, Shahcheraghi F. 2017. Emergence of carbapenem resistant Escherichia coli isolates producing bla NDM and bla OXA-48-like carried on IncA/C and IncL/M plasmids at two Iranian university hospitals. Infect Genet Evol 55:318&#x2013;323. 10.1016/j.meegid.2017.10.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.meegid.2017.10.003</ArticleId><ArticleId IdType="pubmed">28987805</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xe9;rez-L&#xf3;pez A, Sundararaju S, Tsui KM, Al-Mana H, Hasan MR, Suleiman M, Al Maslamani E, Imam O, Roscoe D, Tang P. 2021. Fecal carriage and molecular characterization of carbapenemase-producing Enterobacterales in the pediatric population in Qatar. Microbiol Spectr 9:e0112221. 10.1128/Spectrum.01122-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/Spectrum.01122-21</ArticleId><ArticleId IdType="pmc">PMC8579929</ArticleId><ArticleId IdType="pubmed">34756089</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharahi JY, Hashemi A, Ardebili A, Davoudabadi S. 2021. Molecular characteristics of antibiotic-resistant Escherichia coli and Klebsiella pneumoniae strains isolated from hospitalized patients in Tehran, Iran. Ann Clin Microbiol Antimicrob 20:32. 10.1186/s12941-021-00437-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12941-021-00437-8</ArticleId><ArticleId IdType="pmc">PMC8077724</ArticleId><ArticleId IdType="pubmed">33906654</ArticleId></ArticleIdList></Reference><Reference><Citation>Alqahtani M, Tickler IA, Al Deesi Z, AlFouzan W, Al Jabri A, Al Jindan R, Al Johani S, Alkahtani SA, Al Kharusi A, Mokaddas E, Nabi A, Saeed N, Madian A, Whitmore J, Tenover FC. 2021. Molecular detection of carbapenem resistance genes in rectal swabs from patients in Gulf Cooperation Council hospitals. J Hosp Infect 112:96&#x2013;103. 10.1016/j.jhin.2021.03.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhin.2021.03.027</ArticleId><ArticleId IdType="pubmed">33839212</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Zahrani IA, Alsiri BA. 2018. The emergence of carbapenem-resistant Klebsiella pneumoniae isolates producing OXA-48 and NDM in the Southern (Asir) province, Saudi Arabia. Saudi Med J 39:23&#x2013;30. 10.15537/smj.2018.1.21094.</Citation><ArticleIdList><ArticleId IdType="doi">10.15537/smj.2018.1.21094</ArticleId><ArticleId IdType="pmc">PMC5885116</ArticleId><ArticleId IdType="pubmed">29332105</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosseinzadeh Z, Sedigh Ebrahim-Saraie H, Sarvari J, Mardaneh J, Dehghani B, Rokni-Hosseini SMH, Motamedifar M. 2018. Emerge of bla NDM-1 and bla OXA-48-like harboring carbapenem-resistant Klebsiella pneumoniae isolates from hospitalized patients in southwestern Iran. J Chin Med Assoc 81:536&#x2013;540. 10.1016/j.jcma.2017.08.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcma.2017.08.015</ArticleId><ArticleId IdType="pubmed">29030025</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibl A, Al-Agamy M, Memish Z, Senok A, Khader SA, Assiri A. 2013. The emergence of OXA-48- and NDM-1-positive Klebsiella pneumoniae in Riyadh, Saudi Arabia. Int J Infect Dis 17:e1130&#x2013;e1133. 10.1016/j.ijid.2013.06.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2013.06.016</ArticleId><ArticleId IdType="pubmed">24021566</ArticleId></ArticleIdList></Reference><Reference><Citation>Dortet L, Poirel L, Al Yaqoubi F, Nordmann P. 2012. NDM-1, OXA-48 and OXA-181 carbapenemase-producing Enterobacteriaceae in Sultanate of Oman. Clin Microbiol Infect 18:E144&#x2013;E148. 10.1111/j.1469-0691.2012.03796.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1469-0691.2012.03796.x</ArticleId><ArticleId IdType="pubmed">22404169</ArticleId></ArticleIdList></Reference><Reference><Citation>Matar GM, Cuzon G, Araj GF, Naas T, Corkill J, Kattar MM, Nordmann P. 2008. Oxacillinase-mediated resistance to carbapenems in Klebsiella pneumoniae from Lebanon. Clin Microbiol Infect 14:887&#x2013;888. 10.1111/j.1469-0691.2008.02059.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1469-0691.2008.02059.x</ArticleId><ArticleId IdType="pubmed">18844693</ArticleId></ArticleIdList></Reference><Reference><Citation>Hajj A, Adaim&#xe9; A, Hayajneh W, Abdallah A, Itani T, Hakim&#xe9; N, Mallah M, Alsamarneh R, Badal R, Sarkis DK. 2018. Post Syrian war impact on susceptibility rates and trends in molecular characterization of Enterobacteriaceae. Future Microbiol 13:1419&#x2013;1430. 10.2217/fmb-2018-0109.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fmb-2018-0109</ArticleId><ArticleId IdType="pubmed">30256136</ArticleId></ArticleIdList></Reference><Reference><Citation>Aqel AA, Findlay J, Al-Maayteh M, Al-Kaabneh A, Hopkins KL, Alzoubi H, Masalha I, Turton J, Woodford N, Ellington MJ. 2018. Characterization of carbapenemase-producing Enterobacteriaceae from patients in Amman, Jordan. Microb Drug Resist 24:1121&#x2013;1127. 10.1089/mdr.2017.0238.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/mdr.2017.0238</ArticleId><ArticleId IdType="pubmed">29653473</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta V, Singh M, Datta P, Goel A, Singh S, Prasad K, Chander J. 2020. Detection of various beta-lactamases in Escherichia coli and Klebsiella sp.: a study from tertiary care centre of North India. Indian J Med Microbiol 38:390&#x2013;396. 10.4103/ijmm.IJMM_20_253.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/ijmm.IJMM_20_253</ArticleId><ArticleId IdType="pubmed">33154252</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar C, Mathur P, Venkatesan M, Pragasam AK, Anandan S, Khurana S, Veeraraghavan B. 2019. Rapidly disseminating bla OXA-232 carrying Klebsiella pneumoniae belonging to ST231 in India: multiple and varied mobile genetic elements. BMC Microbiol 19:137. 10.1186/s12866-019-1513-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12866-019-1513-8</ArticleId><ArticleId IdType="pmc">PMC6591861</ArticleId><ArticleId IdType="pubmed">31234800</ArticleId></ArticleIdList></Reference><Reference><Citation>Muktan B, Thapa Shrestha U, Dhungel B, Mishra BC, Shrestha N, Adhikari N, Banjara MR, Adhikari B, Rijal KR, Ghimire P. 2020. Plasmid mediated colistin resistant mcr-1 and co-existence of OXA-48 among Escherichia coli from clinical and poultry isolates: first report from Nepal. Gut Pathog 12:44. 10.1186/s13099-020-00382-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13099-020-00382-5</ArticleId><ArticleId IdType="pmc">PMC7499862</ArticleId><ArticleId IdType="pubmed">32963589</ArticleId></ArticleIdList></Reference><Reference><Citation>Berglund B, Hoang NTB, Tarnberg M, Le NK, Welander J, Nilsson M, Khu DTK, Nilsson LE, Olson L, Le HT, Larsson M, Hanberger H. 2018. Colistin- and carbapenem-resistant Klebsiella pneumoniae carrying mcr-1 and blaOXA-48 isolated at a paediatric hospital in Vietnam. J Antimicrob Chemother 73:1100&#x2013;1102. 10.1093/jac/dkx491.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkx491</ArticleId><ArticleId IdType="pubmed">29253209</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Guo L, Ye K, Yang J. 2021. Genetic characteristics of OXA-48-producing Enterobacterales from China. J Glob Antimicrob Resist 26:285&#x2013;291. 10.1016/j.jgar.2021.07.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jgar.2021.07.006</ArticleId><ArticleId IdType="pubmed">34284128</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu F, Wang S, Lv J, Qi X, Guo Y, Tang YW, Kreiswirth BN, Wang L, Chen L. 2017. Coexistence of OXA-48-producing Klebsiella pneumoniae and Escherichia coli in a hospitalized patient who returned from Europe to China. Antimicrob Agents Chemother 61:e02580-16. 10.1128/AAC.02580-16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.02580-16</ArticleId><ArticleId IdType="pmc">PMC5365688</ArticleId><ArticleId IdType="pubmed">28115343</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Z, Huang H, Xu Y, Wang M, Lv J, Xu L, Shi C, Xu Y, Yang R, Chen L, Du H. 2021. Emergence and genomics of OXA-232-producing Klebsiella pneumoniae in a hospital in Yancheng, China. J Glob Antimicrob Resist 26:194&#x2013;198. 10.1016/j.jgar.2021.05.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jgar.2021.05.015</ArticleId><ArticleId IdType="pubmed">34146740</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Ma W, Qin Q, Liu S, Ye L, Yang J, Li B. 2019. Nosocomial spread of OXA-232-producing Klebsiella pneumoniae ST15 in a teaching hospital, Shanghai, China. BMC Microbiol 19:235. 10.1186/s12866-019-1609-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12866-019-1609-1</ArticleId><ArticleId IdType="pmc">PMC6819465</ArticleId><ArticleId IdType="pubmed">31660869</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia H, Zhang Y, Ye J, Xu W, Xu Y, Zeng W, Liao W, Chen T, Cao J, Wu Q, Zhou T. 2021. Outbreak of multidrug-resistant OXA-232-producing ST15 Klebsiella pneumoniae in a teaching hospital in Wenzhou, China. Infect Drug Resist 14:4395&#x2013;4407. 10.2147/IDR.S329563.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IDR.S329563</ArticleId><ArticleId IdType="pmc">PMC8554319</ArticleId><ArticleId IdType="pubmed">34729016</ArticleId></ArticleIdList></Reference><Reference><Citation>Balm MND, Ngan G, Jureen R, Lin RTP, Teo JWP. 2013. OXA-181-producing Klebsiella pneumoniae establishing in Singapore. BMC Infect Dis 13:58&#x2013;55. 10.1186/1471-2334-13-58.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2334-13-58</ArticleId><ArticleId IdType="pmc">PMC3570352</ArticleId><ArticleId IdType="pubmed">23374756</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagano N, Endoh Y, Nagano Y, Toyama M, Matsui M, Shibayama K, Arakawa Y. 2013. First report of OXA-48 carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in Japan from a patient returned from Southeast Asia. Jpn J Infect Dis 66:79&#x2013;81. 10.7883/yoken.66.79.</Citation><ArticleIdList><ArticleId IdType="doi">10.7883/yoken.66.79</ArticleId><ArticleId IdType="pubmed">23429093</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishida S, Asahara M, Nemoto K, Ishigaki S, Furukawa T, Sano K, Ono Y. 2019. Emergence of Escherichia coli producing OXA-48-like carbapenemase in a patient with percutaneous transhepatic biliary drainage. Infect Prev Pract 1:100008. 10.1016/j.infpip.2019.100008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.infpip.2019.100008</ArticleId><ArticleId IdType="pmc">PMC8336298</ArticleId><ArticleId IdType="pubmed">34368674</ArticleId></ArticleIdList></Reference><Reference><Citation>Humphries RM, Yang S, Hemarajata P, Ward KW, Hindler JA, Miller SA, Gregson A. 2015. First report of ceftazidime-avibactam resistance in a KPC-3-expressing Klebsiella pneumoniae isolate. Antimicrob Agents Chemother 59:6605&#x2013;6607. 10.1128/AAC.01165-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01165-15</ArticleId><ArticleId IdType="pmc">PMC4576121</ArticleId><ArticleId IdType="pubmed">26195508</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyman M, Walters M, Lonsway D, Rasheed K, Limbago B, Kallen A. 2015. Notes from the field: carbapenem-resistant Enterobacteriaceae producing OXA-48-like carbapenemases&#x2014;United States, 2010&#x2013;2015. MMWR Morb Mortal Wkly Rep 64:1315&#x2013;1316. 10.15585/mmwr.mm6447a3.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6447a3</ArticleId><ArticleId IdType="pubmed">26633574</ArticleId></ArticleIdList></Reference><Reference><Citation>Lutgring JD, Zhu W, De Man TJB, Avillan JJ, Anderson KF, Lonsway DR, Rowe LA, Batra D, Rasheed JK, Limbago BM. 2018. Phenotypic and genotypic characterization of Enterobacteriaceae producing oxacillinase-48-like carbapenemases, United States. Emerg Infect Dis 24:700&#x2013;709. 10.3201/eid2404.171377.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2404.171377</ArticleId><ArticleId IdType="pmc">PMC5875285</ArticleId><ArticleId IdType="pubmed">29553324</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyd SE, Livermore DM, Hooper DC, Hope WW. 2020. Metallo-&#x3b2;-lactamases: structure, function, epidemiology, treatment options, and the development pipeline. Antimicrob Agents Chemother 64:e00397-20. 10.1128/AAC.00397-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00397-20</ArticleId><ArticleId IdType="pmc">PMC7508574</ArticleId><ArticleId IdType="pubmed">32690645</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres-Gonzalez P, Cervera-Hernandez ME, Niembro-Ortega MD, Leal-Vega F, Cruz-Hervert LP, Garc&#xed;a-Garc&#xed;a L, Galindo-Fraga A, Martinez-Gamboa A, Bobadilla-Del Valle M, Sifuentes-Osornio J, Ponce-De-Leon A. 2015. Factors associated to prevalence and incidence of carbapenem-resistant Enterobacteriaceae fecal carriage: a cohort study in a Mexican tertiary care hospital. PLoS One 10:e0139883. 10.1371/journal.pone.0139883.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0139883</ArticleId><ArticleId IdType="pmc">PMC4592225</ArticleId><ArticleId IdType="pubmed">26431402</ArticleId></ArticleIdList></Reference><Reference><Citation>Aquino-Andrade A, Merida-Vieyra J, Arias De La Garza E, Arzate-Barbosa P, De Colsa Ranero A. 2018. Carbapenemase-producing Enterobacteriaceae in Mexico: report of seven non-clonal cases in a pediatric hospital. BMC Microbiol 18:38. 10.1186/s12866-018-1166-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12866-018-1166-z</ArticleId><ArticleId IdType="pmc">PMC5907697</ArticleId><ArticleId IdType="pubmed">29673319</ArticleId></ArticleIdList></Reference><Reference><Citation>De Belder D, Ghiglione B, Pasteran F, De Mendieta JM, Corso A, Curto L, Di Bella A, Gutkind G, Gomez SA, Power P. 2020. Comparative kinetic analysis of OXA-438 with related OXA-48-type carbapenem-hydrolyzing class D &#x3b2;-lactamases. ACS Infect Dis 6:3026&#x2013;3033. 10.1021/acsinfecdis.0c00537.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsinfecdis.0c00537</ArticleId><ArticleId IdType="pubmed">32970406</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasteran F, Denorme L, Ote I, Gomez S, De Belder D, Glupczynski Y, Bogaerts P, Ghiglione B, Power P, Mertens P, Corso A. 2016. Rapid identification of OXA-48 and OXA-163 subfamilies in carbapenem-resistant Gram-negative bacilli with a novel immunochromatographic lateral flow assay. J Clin Microbiol 54:2832&#x2013;2836. 10.1128/JCM.01175-16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.01175-16</ArticleId><ArticleId IdType="pmc">PMC5078564</ArticleId><ArticleId IdType="pubmed">27535687</ArticleId></ArticleIdList></Reference><Reference><Citation>Magagnin CM, Rozales FP, Antochevis L, Nunes LS, Martins AS, Barth AL, Sampaio JM, Zavascki AP. 2017. Dissemination of blaOXA-370 gene among several Enterobacteriaceae species in Brazil. Eur J Clin Microbiol Infect Dis 36:1907&#x2013;1910. 10.1007/s10096-017-3012-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10096-017-3012-x</ArticleId><ArticleId IdType="pubmed">28555403</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrasco-Anabal&#xf3;n S, Concei&#xe7;&#xe3;o Neto CO, D'Alincourt Carvalho-Assef AP, Lima CA, Cifuentes M, Silva F, Barrera B, Dom&#xed;nguez M, Gonz&#xe1;lez-Rocha G, Bello-Toledo H. 2019. Introduction of NDM-1 and OXA-370 from Brazil into Chile in strains of Klebsiella pneumoniae isolated from a single patient. Int J Infect Dis 81:28&#x2013;30. 10.1016/j.ijid.2019.01.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2019.01.051</ArticleId><ArticleId IdType="pubmed">30738908</ArticleId></ArticleIdList></Reference><Reference><Citation>Falagas ME, Lourida P, Poulikakos P, Rafailidis PI, Tansarli GS. 2014. Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence. Antimicrob Agents Chemother 58:654&#x2013;663. 10.1128/AAC.01222-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01222-13</ArticleId><ArticleId IdType="pmc">PMC3910850</ArticleId><ArticleId IdType="pubmed">24080646</ArticleId></ArticleIdList></Reference><Reference><Citation>Navarro-San Francisco C, Mora-Rillo M, Romero-G&#xf3;mez MP, Moreno-Ramos F, Rico-Nieto A, Ruiz-Carrascoso G, G&#xf3;mez-Gil R, Arribas-L&#xf3;pez JR, Mingorance J, Pa&#xf1;o-Pardo JR. 2013. Bacteraemia due to OXA-48-carbapenemase-producing Enterobacteriaceae: a major clinical challenge. Clin Microbiol Infect 19:E72&#x2013;E79. 10.1111/1469-0691.12091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1469-0691.12091</ArticleId><ArticleId IdType="pubmed">23231088</ArticleId></ArticleIdList></Reference><Reference><Citation>Guti&#xe9;rrez-Guti&#xe9;rrez B, Salamanca E, de Cueto M, Hsueh P-R, Viale P, Pa&#xf1;o-Pardo JR, Venditti M, Tumbarello M, Daikos G, Cant&#xf3;n R, Doi Y, Tuon FF, Karaiskos I, P&#xe9;rez-Nadales E, Schwaber MJ, Azap &#xd6;K, Souli M, Roilides E, Pournaras S, Akova M, P&#xe9;rez F, Bermejo J, Oliver A, Almela M, Lowman W, Almirante B, Bonomo RA, Carmeli Y, Paterson DL, Pascual A, Rodr&#xed;guez-Ba&#xf1;o J, del Toro MD, G&#xe1;lvez J, Falcone M, Russo A, Giamarellou H, Trecarichi EM, Losito AR, Garc&#xed;a-V&#xe1;zquez E, Hern&#xe1;ndez A, G&#xf3;mez J, Bou G, Iosifidis E, Prim N, Navarro F, Mirelis B, Skiada A, Orig&#xfc;en J, Juan RS, Fern&#xe1;ndez-Ruiz M, et al.. 2017. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infect Dis 17:726&#x2013;734. 10.1016/S1473-3099(17)30228-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(17)30228-1</ArticleId><ArticleId IdType="pubmed">28442293</ArticleId></ArticleIdList></Reference><Reference><Citation>Balkan II, Ayg&#xfc;n G, Ayd&#x131;n S, Mutcal&#x131; SI, Kara Z, Ku&#x15f;kucu M, Midilli K, &#x15e;emen V, Aras &#x15e;, Yemi&#x15f;en M, Mete B, &#xd6;zaras R, Salto&#x11f;lu N, Tabak F, &#xd6;zt&#xfc;rk R. 2014. Blood stream infections due to OXA-48-like carbapenemase-producing Enterobacteriaceae: treatment and survival. Int J Infect Dis 26:51&#x2013;56. 10.1016/j.ijid.2014.05.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2014.05.012</ArticleId><ArticleId IdType="pubmed">24998423</ArticleId></ArticleIdList></Reference><Reference><Citation>Mimoz O, Gr&#xe9;goire N, Poirel L, Marliat M, Couet W, Nordmann P. 2012. Broad-spectrum &#x3b2;-lactam antibiotics for treating experimental peritonitis in mice due to Klebsiella pneumoniae producing the carbapenemase OXA-48. Antimicrob Agents Chemother 56:2759&#x2013;2760. 10.1128/AAC.06069-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.06069-11</ArticleId><ArticleId IdType="pmc">PMC3346608</ArticleId><ArticleId IdType="pubmed">22330912</ArticleId></ArticleIdList></Reference><Reference><Citation>Potron A, Nordmann P, Rondinaud E, Jaureguy F, Poirel L. 2013. A mosaic transposon encoding OXA-48 and CTX-M-15: towards pan-resistance. J Antimicrob Chemother 68:476&#x2013;477. 10.1093/jac/dks397.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dks397</ArticleId><ArticleId IdType="pubmed">23027715</ArticleId></ArticleIdList></Reference><Reference><Citation>Potron A, Poirel L, Rondinaud E, Nordmann P. 2013. Intercontinental spread of OXA-48 beta-lactamase-producing Enterobacteriaceae over a 11-year period, 2001 to 2011. Euro Surveill 18:20549. 10.2807/1560-7917.es2013.18.31.20549.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.es2013.18.31.20549</ArticleId><ArticleId IdType="pubmed">23929228</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes S, Gilchrist M, Heard K, Hamilton R, Sneddon J. 2020. Treating infections caused by carbapenemase-producing Enterobacterales (CPE): a pragmatic approach to antimicrobial stewardship on behalf of the UKCPA Pharmacy Infection Network (PIN). JAC Antimicrob Resist 2:dlaa075. 10.1093/jacamr/dlaa075.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jacamr/dlaa075</ArticleId><ArticleId IdType="pmc">PMC8210165</ArticleId><ArticleId IdType="pubmed">34223030</ArticleId></ArticleIdList></Reference><Reference><Citation>Livermore DM, Mushtaq S, Warner M, Miossec C, Woodford N. 2008. NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum &#x3b2;-lactamases and carbapenemases. J Antimicrob Chemother 62:1053&#x2013;1056. 10.1093/jac/dkn320.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkn320</ArticleId><ArticleId IdType="pubmed">18689875</ArticleId></ArticleIdList></Reference><Reference><Citation>Stachyra T, Levasseur P, P&#xe9;chereau MC, Girard AM, Claudon M, Miossec C, Black MT. 2009. In vitro activity of the &#x3b2;-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases. J Antimicrob Chemother 64:326&#x2013;329. 10.1093/jac/dkp197.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkp197</ArticleId><ArticleId IdType="pmc">PMC2707266</ArticleId><ArticleId IdType="pubmed">19493866</ArticleId></ArticleIdList></Reference><Reference><Citation>Endimiani A, Choudhary Y, Bonomo RA. 2009. In vitro activity of NXL104 in combination with &#x3b2;-lactams against Klebsiella pneumoniae isolates producing KPC carbapenemases. Antimicrob Agents Chemother 53:3599&#x2013;3601. 10.1128/AAC.00641-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00641-09</ArticleId><ArticleId IdType="pmc">PMC2715587</ArticleId><ArticleId IdType="pubmed">19528274</ArticleId></ArticleIdList></Reference><Reference><Citation>Livermore DM, Mushtaq S, Warner M, Zhang J, Maharjan S, Doumith M, Woodford N. 2011. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother 55:390&#x2013;394. 10.1128/AAC.00756-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00756-10</ArticleId><ArticleId IdType="pmc">PMC3019623</ArticleId><ArticleId IdType="pubmed">21041502</ArticleId></ArticleIdList></Reference><Reference><Citation>van Duin D, Bonomo RA. 2016. Ceftazidime/avibactam and ceftolozane/tazobactam: second-generation &#x3b2;-lactam/&#x3b2;-lactamase inhibitor combinations. Clin Infect Dis 63:234&#x2013;241. 10.1093/cid/ciw243.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciw243</ArticleId><ArticleId IdType="pmc">PMC4928383</ArticleId><ArticleId IdType="pubmed">27098166</ArticleId></ArticleIdList></Reference><Reference><Citation>Sousa A, P&#xe9;rez-Rodr&#xed;guez MT, Soto A, Rodr&#xed;guez L, P&#xe9;rez-Landeiro A, Mart&#xed;nez-Lamas L, Nodar A, Crespo M. 2018. Effectiveness of ceftazidime/avibactam as salvage therapy for treatment of infections due to OXA-48 carbapenemase-producing Enterobacteriaceae. J Antimicrob Chemother 73:3170&#x2013;3175. 10.1093/jac/dky295.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dky295</ArticleId><ArticleId IdType="pubmed">30099490</ArticleId></ArticleIdList></Reference><Reference><Citation>Cast&#xf3;n JJ, Lacort-Peralta I, Mart&#xed;n-D&#xe1;vila P, Loeches B, Tabares S, Temkin L, Torre-Cisneros J, Pa&#xf1;o-Pardo JR. 2017. Clinical efficacy of ceftazidime/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients. Int J Infect Dis 59:118&#x2013;123. 10.1016/j.ijid.2017.03.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2017.03.021</ArticleId><ArticleId IdType="pubmed">28392315</ArticleId></ArticleIdList></Reference><Reference><Citation>Alraddadi BM, Saeedi M, Qutub M, Alshukairi A, Hassanien A, Wali G. 2019. Efficacy of ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae. BMC Infect Dis 19:772. 10.1186/s12879-019-4409-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-019-4409-1</ArticleId><ArticleId IdType="pmc">PMC6724371</ArticleId><ArticleId IdType="pubmed">31484510</ArticleId></ArticleIdList></Reference><Reference><Citation>Temkin E, Torre-Cisneros J, Beovic B, Benito N, Giannella M, Gilarranz R, Jeremiah C, Loeches B, MacHuca I, Jim&#xe9;nez-Mart&#xed;n MJ, Mart&#xed;nez JA, Mora-Rillo M, Navas E, Osthoff M, Pozo JC, Ramos JCR, Rodriguez M, S&#xe1;nchez-Garc&#xed;a M, Viale P, Wolff M, Carmeli Y. 2017. Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms. Antimicrob Agents Chemother 61:e01964-16. 10.1128/AAC.01964-16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01964-16</ArticleId><ArticleId IdType="pmc">PMC5278727</ArticleId><ArticleId IdType="pubmed">27895014</ArticleId></ArticleIdList></Reference><Reference><Citation>Fr&#xf6;hlich C, S&#xf8;rum V, Thomassen AM, Johnsen PJ, Leiros H-KS, Samuelsen &#xd8;. 2019. OXA-48-mediated ceftazidime-avibactam resistance is associated with evolutionary trade-offs. mSphere 4:e00024-19. 10.1128/mSphere.00024-19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mSphere.00024-19</ArticleId><ArticleId IdType="pmc">PMC6437269</ArticleId><ArticleId IdType="pubmed">30918055</ArticleId></ArticleIdList></Reference><Reference><Citation>Shapiro AB, Moussa SH, Carter NM, Gao N, Miller AA. 2021. Ceftazidime-avibactam resistance mutations V240G, D179Y, and D179Y/T243M in KPC-3 &#x3b2;-lactamase do not alter cefpodoxime-ETX1317 susceptibility. ACS Infect Dis 7:79&#x2013;87. 10.1021/acsinfecdis.0c00575.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsinfecdis.0c00575</ArticleId><ArticleId IdType="pubmed">33291867</ArticleId></ArticleIdList></Reference><Reference><Citation>Palwe S, Veeraraghavan B, Periasamy H, Khobragade K, Kharat AS. 2020. Unorthodox parenteral &#x3b2;-lactam and &#x3b2;-lactamase inhibitor combinations: flouting antimicrobial stewardship and compromising patient care. Antimicrob Agents Chemother 64:e00168-20. 10.1128/AAC.00168-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00168-20</ArticleId><ArticleId IdType="pmc">PMC7179625</ArticleId><ArticleId IdType="pubmed">32122901</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghafur A, Tayade A, Kannaian P. 2012. Clinical profile of patients treated with cefepime/tazobactam: a new &#xdf;-lactam/&#xdf;-lactamase inhibitor combination. J Microbiol Infect Dis 2:79&#x2013;86. 10.5799/ahinjs.02.2012.03.0049.</Citation><ArticleIdList><ArticleId IdType="doi">10.5799/ahinjs.02.2012.03.0049</ArticleId></ArticleIdList></Reference><Reference><Citation>Gill CM, Abdelraouf K, Nicolau DP. 2021. In vivo activity of WCK 4282 (high-dose cefepime/tazobactam) against serine &#x3b2;-lactamase-producing Enterobacterales and Pseudomonas aeruginosa in the neutropenic murine thigh infection model. J Antimicrob Chemother 76:993&#x2013;1000. 10.1093/jac/dkaa551.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkaa551</ArticleId><ArticleId IdType="pubmed">33438033</ArticleId></ArticleIdList></Reference><Reference><Citation>Mushtaq S, Garello P, Vickers A, Woodford N, Livermore DM. 2021. Cefepime/tazobactam compared with other tazobactam combinations against problem Gram-negative bacteria. Int J Antimicrob Agents 57:106318. 10.1016/j.ijantimicag.2021.106318.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2021.106318</ArticleId><ArticleId IdType="pubmed">33716176</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. National Library of Medicine. 2018. Study of cefepime-tazobactam (FEP-TAZ) in complicated urinary tract infection (cUTI) or acute pyelonephritis (AP). https://clinicaltrials.gov/ct2/show/NCT03630081. Accessed 6 February 2022.</Citation></Reference><Reference><Citation>Livermore DM, Mushtaq S, Meunier D, Hopkins KL, Hill R, Adkin R, Chaudhry A, Pike R, Staves P, Woodford N, Allen M, Brown DFG, Livermore DM, Longshaw C, MacGowan APG, BSAC Resistance Surveillance Standing Committee. 2017. Activity of ceftolozane/tazobactam against surveillance and &#x201c;problem&#x201d; Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles. J Antimicrob Chemother 72:2278&#x2013;2289. 10.1093/jac/dkx136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkx136</ArticleId><ArticleId IdType="pmc">PMC5890766</ArticleId><ArticleId IdType="pubmed">28520867</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito A, Kohira N, Bouchillon SK, West J, Rittenhouse S, Sader HS, Rhomberg PR, Jones RN, Yoshizawa H, Nakamura R, Tsuji M, Yamano Y. 2016. In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria. J Antimicrob Chemother 71:670&#x2013;677. 10.1093/jac/dkv402.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkv402</ArticleId><ArticleId IdType="pubmed">26645269</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs MR, Abdelhamed AM, Good CE, Rhoads DD, Hujer KM, Hujer AM, Domitrovic TN, Rudin SD, Richter SS, van Duin D, Kreiswirth BN, Greco C, Fouts DE, Bonomo RA. 2019. ARGONAUT-I: activity of cefiderocol (s-649266), a siderophore cephalosporin, against Gram-negative bacteria, including carbapenem-resistant nonfermenters and Enterobacteriaceae with defined extended-spectrum &#x3b2;-lactamases and carbapenemases. Antimicrob Agents Chemother 63:e01801-18. 10.1128/AAC.01801-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01801-18</ArticleId><ArticleId IdType="pmc">PMC6325197</ArticleId><ArticleId IdType="pubmed">30323050</ArticleId></ArticleIdList></Reference><Reference><Citation>Poirel L, Kieffer N, Nordmann P. 2018. Stability of cefiderocol against clinically significant broad-spectrum oxacillinases. Int J Antimicrob Agents 52:866&#x2013;867. 10.1016/j.ijantimicag.2018.11.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2018.11.005</ArticleId><ArticleId IdType="pubmed">30415004</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu JY, Srinivas P, Pogue JM. 2020. Cefiderocol: a novel agent for the management of multidrug-resistant Gram-negative organisms. Infect Dis Ther 9:17&#x2013;40. 10.1007/s40121-020-00286-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40121-020-00286-6</ArticleId><ArticleId IdType="pmc">PMC7054475</ArticleId><ArticleId IdType="pubmed">32072491</ArticleId></ArticleIdList></Reference><Reference><Citation>Bassetti M, Echols R, Matsunaga Y, Ariyasu M, Doi Y, Ferrer R, Lodise TP, Naas T, Niki Y, Paterson DL, Portsmouth S, Torre-Cisneros J, Toyoizumi K, Wunderink RG, Nagata TD. 2021. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis 21:226&#x2013;240. 10.1016/S1473-3099(20)30796-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30796-9</ArticleId><ArticleId IdType="pubmed">33058795</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein S, Boutin S, Kocer K, Fiedler MO, St&#xf6;rzinger D, Weigand MA, Tan B, Richter D, Rupp C, Mieth M, Mehrabi A, Hackert T, Zimmermann S, Heeg K, Nurjadi D. 2021. Rapid development of cefiderocol resistance in carbapenem-resistant Enterobacter cloacae during therapy is associated with heterogeneous mutations in the catecholate siderophore receptor cirA. Clin Infect Dis 74:905&#x2013;908. 10.1093/cid/ciab511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab511</ArticleId><ArticleId IdType="pmc">PMC8906715</ArticleId><ArticleId IdType="pubmed">34079986</ArticleId></ArticleIdList></Reference><Reference><Citation>Aishwarya KVL, Geetha PV, Eswaran S, Mariappan S, Sekar U. 2020. Spectrum of aminoglycoside modifying enzymes in Gram-negative bacteria causing human infections. J Lab Physicians 12:27&#x2013;31. 10.1055/s-0040-1713687.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0040-1713687</ArticleId><ArticleId IdType="pmc">PMC7419166</ArticleId><ArticleId IdType="pubmed">32792790</ArticleId></ArticleIdList></Reference><Reference><Citation>Galani I, Nafplioti K, Adamou P, Karaiskos I, Giamarellou H, Souli M, Study Collaborators. 2019. Nationwide epidemiology of carbapenem resistant Klebsiella pneumoniae isolates from Greek hospitals, with regard to plazomicin and aminoglycoside resistance. BMC Infect Dis 19:167. 10.1186/s12879-019-3801-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-019-3801-1</ArticleId><ArticleId IdType="pmc">PMC6377745</ArticleId><ArticleId IdType="pubmed">30770727</ArticleId></ArticleIdList></Reference><Reference><Citation>Galani I, Anagnostoulis G, Chatzikonstantinou M, Petrikkos G, Souli M. 2016. Emergence of Klebsiella pneumoniae co-producing OXA-48, CTX-M-15, and ArmA in Greece. Clin Microbiol Infect 22:898&#x2013;899. 10.1016/j.cmi.2016.08.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2016.08.002</ArticleId><ArticleId IdType="pubmed">27542333</ArticleId></ArticleIdList></Reference><Reference><Citation>Elshamy AA, Saleh SE, Alshahrani MY, Aboshanab KM, Aboulwafa MM, Hassouna NA. 2021. OXA-48 carbapenemase-encoding transferable plasmids of Klebsiella pneumoniae recovered from Egyptian patients suffering from complicated urinary tract infections. Biology 10:889. 10.3390/biology10090889.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biology10090889</ArticleId><ArticleId IdType="pmc">PMC8469419</ArticleId><ArticleId IdType="pubmed">34571766</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelaziz SM, Aboshanab KM, Yahia IS, Yassien MA, Hassouna NA. 2021. Correlation between the antibiotic resistance genes and susceptibility to antibiotics among the carbapenem-resistant Gram-negative pathogens. Antibiotics 10:255&#x2013;215. 10.3390/antibiotics10030255.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antibiotics10030255</ArticleId><ArticleId IdType="pmc">PMC8001261</ArticleId><ArticleId IdType="pubmed">33806340</ArticleId></ArticleIdList></Reference><Reference><Citation>ElBaradei A, Shawky SM. 2022. Co-existence of blaOXA-48, rmtB and armA among Klebsiella pneumoniae isolates causing respiratory tract infections in Alexandria, Egypt. J Med Microbiol 31:23&#x2013;28. 10.21608/ejmm.2022.228619.</Citation><ArticleIdList><ArticleId IdType="doi">10.21608/ejmm.2022.228619</ArticleId></ArticleIdList></Reference><Reference><Citation>Evren E, Azap OK, &#xc7;olako&#x11f;lu &#x15e;, Arslan H. 2013. In vitro activity of fosfomycin in combination with imipenem, meropenem, colistin and tigecycline against OXA 48-positive Klebsiella pneumoniae strains. Diagn Microbiol Infect Dis 76:335&#x2013;338. 10.1016/j.diagmicrobio.2013.04.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diagmicrobio.2013.04.004</ArticleId><ArticleId IdType="pubmed">23726147</ArticleId></ArticleIdList></Reference><Reference><Citation>Singkham-In U, Muhummudaree N, Chatsuwan T. 2021. In vitro synergism of azithromycin combination with antibiotics against OXA-48-producing Klebsiella pneumoniae clinical isolates. Antibiotics 10:1551. 10.3390/antibiotics10121551.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antibiotics10121551</ArticleId><ArticleId IdType="pmc">PMC8698995</ArticleId><ArticleId IdType="pubmed">34943763</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazmierczak KM, Bradford PA, Stone GG, De Jonge BLM, Sahm DF. 2018. In vitro activity of ceftazidime-avibactam and aztreonam-avibactam against OXA-48-carrying Enterobacteriaceae isolated as part of the International Network for Optimal Resistance Monitoring (INFORM) global surveillance program from 2012 to 2015. Antimicrob Agents Chemother 62:e00592-18. 10.1128/AAC.00592-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00592-18</ArticleId><ArticleId IdType="pmc">PMC6256811</ArticleId><ArticleId IdType="pubmed">30249690</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozbek B, Mataraci-Kara E, Er S, Ozdamar M, Yilmaz M. 2015. In vitro activities of colistin, tigecycline and tobramycin, alone or in combination, against carbapenem-resistant Enterobacteriaceae strains. J Glob Antimicrob Resist 3:278&#x2013;282. 10.1016/j.jgar.2015.09.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jgar.2015.09.001</ArticleId><ArticleId IdType="pubmed">27842873</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixit D, Madduri RP, SharMA R. 2014. The role of tigecycline in the treatment of infections in light of the new black box warning. Expert Rev Anti Infect Ther 12:397&#x2013;400. 10.1586/14787210.2014.894882.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14787210.2014.894882</ArticleId><ArticleId IdType="pubmed">24597542</ArticleId></ArticleIdList></Reference><Reference><Citation>Mataraci Kara E, Yilmaz M, Istanbullu Tosun A, &#xd6;zbek &#xc7;elik B. 2020. Evaluation of the synergy of ceftazidime/avibactam in combination with colistin, doripenem, levofloxacin, tigecycline, and tobramycin against OXA-48 producing Enterobacterales. J Chemother 32:171&#x2013;178. 10.1080/1120009X.2020.1761172.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1120009X.2020.1761172</ArticleId><ArticleId IdType="pubmed">32375606</ArticleId></ArticleIdList></Reference><Reference><Citation>Grossman TH, Starosta AL, Fyfe C, O'Brien W, Rothstein DM, Mikolajka A, Wilson DN, Sutcliffe JA. 2012. Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic. Antimicrob Agents Chemother 56:2559&#x2013;2564. 10.1128/AAC.06187-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.06187-11</ArticleId><ArticleId IdType="pmc">PMC3346605</ArticleId><ArticleId IdType="pubmed">22354310</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrissey I, Olesky M, Hawser S, Lob SH, Karlowsky JA, Corey GR, Bassetti M, Fyfe C. 2020. In vitro activity of eravacycline against Gram-negative bacilli isolated in clinical laboratories worldwide from 2013 to 2017. Antimicrob Agents Chemother 64:e01699. 10.1128/AAC.01699-19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01699-19</ArticleId><ArticleId IdType="pmc">PMC7038303</ArticleId><ArticleId IdType="pubmed">31843999</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhanel GG, Cheung D, Adam H, Zelenitsky S, Golden A, Schweizer F, Gorityala B, Lagac&#xe9;-Wiens PRS, Walkty A, Gin AS, Hoban DJ, Karlowsky JA. 2016. Review of eravacycline, a novel fluorocycline antibacterial agent. Drugs 76:567&#x2013;588. 10.1007/s40265-016-0545-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-016-0545-8</ArticleId><ArticleId IdType="pubmed">26863149</ArticleId></ArticleIdList></Reference><Reference><Citation>Hobbs ALV, Gelfand MS, Cleveland KO, Saddler K, Sierra-Hoffman MA. 2021. A retrospective, multicentre evaluation of eravacycline utilisation in community and academic hospitals. J Glob Antimicrob 29:430&#x2013;433. 10.1016/j.jgar.2021.10.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jgar.2021.10.020</ArticleId><ArticleId IdType="pubmed">34788691</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomkin JS, Gardovskis J, Lawrence K, Montravers P, Sway A, Evans D, Tsai L. 2019. IGNITE4: results of a phase 3, randomized, multicenter, prospective trial of eravacycline vs meropenem in the treatment of complicated intraabdominal infections. Clin Infect Dis 69:921&#x2013;929. 10.1093/cid/ciy1029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciy1029</ArticleId><ArticleId IdType="pmc">PMC6735687</ArticleId><ArticleId IdType="pubmed">30561562</ArticleId></ArticleIdList></Reference><Reference><Citation>Doi Y. 2019. Treatment options for carbapenem-resistant Gram-negative bacterial infections. Clin Infect Dis 69:S565&#x2013;S575. 10.1093/cid/ciz830.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciz830</ArticleId><ArticleId IdType="pmc">PMC6853760</ArticleId><ArticleId IdType="pubmed">31724043</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim DH, Lees WJ, Kempsell KE, Lane WS, Duncan K, Walsh CT. 1996. Characterization of a Cys115 to Asp substitution in the Escherichia coli cell wall biosynthetic enzyme UDP-GlcNAc enolpyruvyl transferase (MurA) that confers resistance to inactivation by the antibiotic fosfomycin. Biochemistry 35:4923&#x2013;4928. 10.1021/bi952937w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi952937w</ArticleId><ArticleId IdType="pubmed">8664284</ArticleId></ArticleIdList></Reference><Reference><Citation>Berleur M, Gu&#xe9;rin F, Massias L, Chau F, Poujade J, Cattoir V, Fantin B, de Lastours V. 2018. Activity of fosfomycin alone or combined with temocillin in vitro and in a murine model of peritonitis due to KPC-3- or OXA-48-producing Escherichia coli. J Antimicrob Chemother 73:3074&#x2013;3080. 10.1093/jac/dky283.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dky283</ArticleId><ArticleId IdType="pubmed">30085154</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. National Library of Medicine. 2016. Fosfomycin i.v. for treatment of severely infected patients (FORTRESS). https://clinicaltrials.gov/ct2/show/NCT02979951. Accessed 6 February 2022.</Citation></Reference><Reference><Citation>Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A, Spanu T, Ambretti S, Ginocchio F, Cristini F, Losito AR, Tedeschi S, Cauda R, Bassetti M. 2012. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 55:943&#x2013;950. 10.1093/cid/cis588.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/cis588</ArticleId><ArticleId IdType="pubmed">22752516</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez-Ba&#xf1;o J, Guti&#xe9;rrez-Guti&#xe9;rrez B, Machuca I, Pascual A. 2018. Treatment of infections caused by extended-spectrum-beta-lactamase-, AmpC-, and carbapenemase-producing Enterobacteriaceae. Clin Microbiol Rev 31:e00079-17. 10.1128/CMR.00079-17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.00079-17</ArticleId><ArticleId IdType="pmc">PMC5967687</ArticleId><ArticleId IdType="pubmed">29444952</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahn C, Butt AA, Rivera JI, Yaqoob M, Hag S, Khalil A, Pitout M, Doi Y. 2015. OXA-48-producing Enterobacteriaceae causing bacteremia, United Arab Emirates. Int J Infect Dis 30:e36&#x2013;e37. 10.1016/j.ijid.2014.11.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2014.11.008</ArticleId><ArticleId IdType="pmc">PMC4298473</ArticleId><ArticleId IdType="pubmed">25462183</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyd S, Johnson A, McEntee L, Farrington N, Harper N, Unsworth J, Jimenez-Valverde A, Barrera-Briceno L, Healy F, Xuan L, Peck R, Hope W. 2022. Pharmacodynamics of meropenem against Enterobacterales producing OXA-48 with low meropenem minimum inhibitory concentrations, poster 4027, p 1239. 32nd Eur Congr Clin Microbiol Infect Dis, Lisbon, Portugal.</Citation></Reference><Reference><Citation>Wiskirchen DE, Nordmann P, Crandon JL, Nicolau DP. 2014. Efficacy of humanized carbapenem and ceftazidime regimens against Enterobacteriaceae producing OXA-48 carbapenemase in a murine infection model. Antimicrob Agents Chemother 58:1678&#x2013;1683. 10.1128/AAC.01947-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01947-13</ArticleId><ArticleId IdType="pmc">PMC3957853</ArticleId><ArticleId IdType="pubmed">24379200</ArticleId></ArticleIdList></Reference><Reference><Citation>Erdem F, Abulaila A, Aktas Z, Oncul O. 2020. In vitro evaluation of double carbapenem and colistin combinations against OXA-48, NDM carbapenemase-producing colistin-resistant Klebsiella pneumoniae strains. Antimicrob Resist Infect Control 9:70. 10.1186/s13756-020-00727-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13756-020-00727-4</ArticleId><ArticleId IdType="pmc">PMC7238654</ArticleId><ArticleId IdType="pubmed">32430058</ArticleId></ArticleIdList></Reference><Reference><Citation>Poirel L, Kieffer N, Nordmann P. 2016. In vitro evaluation of dual carbapenem combinations against carbapenemase-producing Enterobacteriaceae. J Antimicrob Chemother 71:156&#x2013;161. 10.1093/jac/dkv294.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkv294</ArticleId><ArticleId IdType="pubmed">26416781</ArticleId></ArticleIdList></Reference><Reference><Citation>Darlow CA, Hope W. 2022. Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales. J Antimicrob Chemother 77:711&#x2013;718. 10.1093/jac/dkab468.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkab468</ArticleId><ArticleId IdType="pmc">PMC8864998</ArticleId><ArticleId IdType="pubmed">34969066</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamrick JC, Docquier JD, Uehara T, Myers CL, Six DA, Chatwin CL, John KJ, Vernacchio SF, Cusick SM, Trout REL, Pozzi C, De Luca F, Benvenuti M, Mangani S, Liu B, Jackson RW, Moeck G, Xerri L, Burns CJ, Pevear DC, Daigle DM. 2020. VNRX-5133 (taniborbactam), a broad-spectrum inhibitor of serine- and metallo-&#x3b2;-lactamases, restores activity of cefepime in Enterobacterales and Pseudomonas aeruginosa. Antimicrob Agents Chemother 64:e01963-19. 10.1128/AAC.01963-19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01963-19</ArticleId><ArticleId IdType="pmc">PMC7038240</ArticleId><ArticleId IdType="pubmed">31871094</ArticleId></ArticleIdList></Reference><Reference><Citation>Mushtaq S, Vickers A, Doumith M, Ellington MJ, Woodford N, Livermore DM. 2021. Activity of &#x3b2;-lactam/taniborbactam (VNRX-5133) combinations against carbapenem-resistant Gram-negative bacteria. J Antimicrob Chemother 76:160&#x2013;170. 10.1093/jac/dkaa391.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkaa391</ArticleId><ArticleId IdType="pubmed">33305800</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. National Library of Medicine. 2019. Safety and efficacy study of cefepime/VNRX-5133 in patients with complicated urinary tract infections (CERTAIN-1). https://clinicaltrials.gov/ct2/show/NCT03840148. Accessed 6 February 2022.</Citation></Reference><Reference><Citation>Sader HS, Rhomberg PR, Flamm RK, Jones RN, Castanheira M. 2017. WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant &#x3b2;-lactamases. J Antimicrob Chemother 72:1696&#x2013;1703. 10.1093/jac/dkx050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkx050</ArticleId><ArticleId IdType="pubmed">28333332</ArticleId></ArticleIdList></Reference><Reference><Citation>Livermore DM, Mushtaq S, Warner M, Vickers A, Woodford N. 2017. In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria. J Antimicrob Chemother 72:1373&#x2013;1385. 10.1093/jac/dkw593.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkw593</ArticleId><ArticleId IdType="pubmed">28158732</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. National Library of Medicine. 2021. Study of cefepime-zidebactam (FEP-ZID) in complicated urinary tract infection (cUTI) or acute pyelonephritis (AP). https://clinicaltrials.gov/ct2/show/NCT04979806. Accessed 6 February 2022.</Citation></Reference><Reference><Citation>Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA. 2011. Carbapenems: past, present, and future. Antimicrob Agents Chemother 55:4943&#x2013;4960. 10.1128/AAC.00296-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00296-11</ArticleId><ArticleId IdType="pmc">PMC3195018</ArticleId><ArticleId IdType="pubmed">21859938</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Angelo RG, Johnson JK, Bork JT, Heil EL. 2016. Treatment options for extended-spectrum beta-lactamase (ESBL) and AmpC-producing bacteria. Expert Opin Pharmacother 17:953&#x2013;967. 10.1517/14656566.2016.1154538.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14656566.2016.1154538</ArticleId><ArticleId IdType="pubmed">26891857</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrissey I, Magnet S, Hawser S, Shapiro S, Knechtle P. 2019. In vitro activity of cefepime-enmetazobactam against Gram-negative isolates collected from U.S. and European hospitals during 2014&#x2013;2015. Antimicrob Agents Chemother 63:e00514-19. 10.1128/AAC.00514-19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00514-19</ArticleId><ArticleId IdType="pmc">PMC6591593</ArticleId><ArticleId IdType="pubmed">30988152</ArticleId></ArticleIdList></Reference><Reference><Citation>Carmeli Y, Adler A, Rashi E, Pypstra R, Shapiro S. 2018. In vitro activity of cefepime-AAI101 vs. drug-resistant Klebsiella pneumoniae clinical isolates, poster. Eur Congr Clin Microbiol Infect Dis, Madrid, Spain.</Citation></Reference><Reference><Citation>Kaye K, Belley A, Lahlou O, Motta P, Kashap S, Knechtle P, Velicitat P. 2020. Outcomes of the novel &#x3b2;-lactam/&#x3b2;-lactamase inhibitor combination of cefepime-enmetazobactam versus piperacillin-tazobactam in adult patients with complicated urinary tract infections&#x2014;the ALLIUM phase 3 trial. 30th Eur Congr Clin Microbiol Infect Dis.</Citation></Reference><Reference><Citation>Das S, Fitzgerald R, Ullah A, Bula M, Collins AM, Mitsi E, Reine J, Hill H, Rylance J, Ferreira DM, Tripp K, Bertasini A, Franzoni S, Massimiliano M, Lahlou O, Motta P, Barth P, Velicitat P, Knechtle P, Hope W. 2020. Intrapulmonary pharmacokinetics of cefepime and enmetazobactam in healthy volunteers: towards new treatments for nosocomial pneumonia. Antimicrob Agents Chemother 65:e01468-20. 10.1128/AAC.01468-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01468-20</ArticleId><ArticleId IdType="pmc">PMC7927813</ArticleId><ArticleId IdType="pubmed">33077666</ArticleId></ArticleIdList></Reference><Reference><Citation>Sader HS, Carvalhaes CG, Arends SJR, Castanheira M, Mendes RE. 2021. Aztreonam/avibactam activity against clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019. J Antimicrob Chemother 76:659&#x2013;666. 10.1093/jac/dkaa504.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkaa504</ArticleId><ArticleId IdType="pubmed">33276387</ArticleId></ArticleIdList></Reference><Reference><Citation>Periasamy H, Joshi P, Palwe S, Shrivastava R, Bhagwat S, Patel M. 2020. High prevalence of Escherichia coli clinical isolates in India harbouring four amino acid inserts in PBP3 adversely impacting activity of aztreonam/avibactam. J Antimicrob Chemother 75:1650&#x2013;1651. 10.1093/jac/dkaa021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkaa021</ArticleId><ArticleId IdType="pubmed">32040179</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordmann P, Yao Y, Falgenhauer L, Sadek M, Imirzalioglu C, Chakraborty T. 2021. Recent emergence of aztreonam-avibactam resistance in NDM and OXA-48 carbapenemase-producing Escherichia coli in Germany. Antimicrob Agents Chemother 65:e0109021. 10.1128/AAC.01090-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01090-21</ArticleId><ArticleId IdType="pmc">PMC8522741</ArticleId><ArticleId IdType="pubmed">34424048</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhagwat SS, Hariharan P, Joshi PR, Palwe SR, Shrivastava R, Patel MV, Devanga Ragupathi NK, Bakthavatchalam YD, Ramesh MS, Soman R, Veeraraghavan B. 2020. Activity of cefepime/zidebactam against MDR Escherichia coli isolates harbouring a novel mechanism of resistance based on four-amino-acid inserts in PBP3. J Antimicrob Chemother 75:3563&#x2013;3567. 10.1093/jac/dkaa353.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkaa353</ArticleId><ArticleId IdType="pubmed">32772098</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Jin L, Sun S, Yin Y, Wang R, Chen F, Wang X, Zhang Y, Hou J, Zhang Y, Zhang Z, Luo L, Guo Z, Li Z, Lin X, Bi L, Wang H. 2022. Occurrence of high levels of cefiderocol resistance in carbapenem-resistant Escherichia coli before its approval in China: a report from China CRE-Network. Microbiol Spectr 10:e0267021. 10.1128/spectrum.02670-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/spectrum.02670-21</ArticleId><ArticleId IdType="pmc">PMC9241927</ArticleId><ArticleId IdType="pubmed">35481835</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsivkovski R, Totrov M, Lomovskaya O. 2020. Biochemical characterization of QPX7728, a new ultrabroad-spectrum beta-lactamase inhibitor of serine and metallo-beta-lactamases. Antimicrob Agents Chemother 64:e00130-20. 10.1128/AAC.00130-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00130-20</ArticleId><ArticleId IdType="pmc">PMC7269513</ArticleId><ArticleId IdType="pubmed">32152086</ArticleId></ArticleIdList></Reference><Reference><Citation>Lomovskaya O, Rubio-Aparicio D, Nelson K, Sun D, Tsivkovski R, Castanheira M, Lindley J, Loutit J, Dudley M. 2021. In vitro activity of the ultrabroad-spectrum beta-lactamase inhibitor QPX7728 in combination with multiple beta-lactam antibiotics against Pseudomonas aeruginosa. Antimicrob Agents Chemother 65:e00210-21. 10.1128/AAC.00210-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00210-21</ArticleId><ArticleId IdType="pmc">PMC8315991</ArticleId><ArticleId IdType="pubmed">33782010</ArticleId></ArticleIdList></Reference><Reference><Citation>Yahav D, Giske CG, Gramatniece A, Abodakpi H, Tam VH, Leibovici L. 2021. New &#x3b2;-lactam&#x2013;&#x3b2;-lactamase inhibitor combinations. Clin Microbiol Rev 34:e00015-20. 10.1128/CMR.00115-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.00115-20</ArticleId><ArticleId IdType="pmc">PMC7849239</ArticleId><ArticleId IdType="pubmed">33504504</ArticleId></ArticleIdList></Reference><Reference><Citation>Potron A, Poirel L, Bussy F, Nordmann P. 2011. Occurrence of the carbapenem-hydrolyzing &#x3b2;-lactamase gene blaOXA-48 in the environment in Morocco. Antimicrob Agents Chemother 55:5413&#x2013;5414. 10.1128/AAC.05120-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.05120-11</ArticleId><ArticleId IdType="pmc">PMC3195045</ArticleId><ArticleId IdType="pubmed">21876064</ArticleId></ArticleIdList></Reference><Reference><Citation>Galler H, Feierl G, Petternel C, Reinthaler FF, Haas D, Grisold AJ, Luxner J, Zarfel G. 2014. KPC-2 and OXA-48 carbapenemase-harbouring Enterobacteriaceae detected in an Austrian wastewater treatment plant. Clin Microbiol Infect 20:O132&#x2013;O134. 10.1111/1469-0691.12336.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1469-0691.12336</ArticleId><ArticleId IdType="pubmed">24033741</ArticleId></ArticleIdList></Reference><Reference><Citation>Tafoukt R, Touati A, Leangapichart T, Bakour S, Rolain JM. 2017. Characterization of OXA-48-like-producing Enterobacteriaceae isolated from river water in Algeria. Water Res 120:185&#x2013;189. 10.1016/j.watres.2017.04.073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.watres.2017.04.073</ArticleId><ArticleId IdType="pubmed">28486169</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasri E, Subirats J, S&#xe0;nchez-Melsi&#xf3; A, Mansour H, Ben Borrego CM, Balc&#xe1;zar JL. 2017. Abundance of carbapenemase genes (bla KPC, bla NDM and bla OXA-48) in wastewater effluents from Tunisian hospitals. Environ Pollut 229:371&#x2013;374. 10.1016/j.envpol.2017.05.095.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.envpol.2017.05.095</ArticleId><ArticleId IdType="pubmed">28614760</ArticleId></ArticleIdList></Reference><Reference><Citation>Nurjadi D, Scherrer M, Frank U, Mutters NT, Heininger A, Sp&#xe4;th I, Eichel VM, Jabs J, Probst K, M&#xfc;ller-Tidow C, Brandt J, Heeg K, Boutin S. 2021. Genomic investigation and successful containment of an intermittent common source outbreak of OXA-48-producing Enterobacter cloacae related to hospital shower drains. Microbiol Spectr 9:e01380-21. 10.1128/Spectrum.01380-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/Spectrum.01380-21</ArticleId><ArticleId IdType="pmc">PMC8612159</ArticleId><ArticleId IdType="pubmed">34817232</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang A, Call DR, Besser TE, Liu J, Jones L, Wang H, Davis MA. 2019. &#x3b2;-Lactam resistance genes in bacteriophage and bacterial DNA from wastewater, river water, and irrigation water in Washington State. Water Res 161:335&#x2013;340. 10.1016/j.watres.2019.06.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.watres.2019.06.026</ArticleId><ArticleId IdType="pubmed">31212239</ArticleId></ArticleIdList></Reference><Reference><Citation>Regev-Yochay G, Smollan G, Tal I, Pinas Zade N, Haviv Y, Nudelman V, Gal-Mor O, Jaber H, Zimlichman E, Keller N, Rahav G. 2018. Sink traps as the source of transmission of OXA-48-producing Serratia marcescens in an intensive care unit. Infect Control Hosp Epidemiol 39:1307&#x2013;1315. 10.1017/ice.2018.235.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/ice.2018.235</ArticleId><ArticleId IdType="pubmed">30284524</ArticleId></ArticleIdList></Reference><Reference><Citation>Jolivet S, Couturier J, Vuillemin X, Gouot C, Nesa D, Adam M, Brissot E, Mohty M, Bonnin RA, Dortet L, Barbut F. 2021. Outbreak of OXA-48-producing Enterobacterales in a haematological ward associated with an uncommon environmental reservoir, France, 2016&#x2013;2019. Euro Surveill 26:2000118. 10.2807/1560-7917.ES.2021.26.21.2000118.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2021.26.21.2000118</ArticleId><ArticleId IdType="pmc">PMC8161731</ArticleId><ArticleId IdType="pubmed">34047273</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahon BM, Brehony C, Cahill N, McGrath E, O'Connor L, Varley A, Cormican M, Ryan S, Hickey P, Keane S, Mulligan M, Ruane B, Jolley KA, Maiden MC, Brisse S, Morris D. 2019. Detection of OXA-48-like-producing Enterobacterales in Irish recreational water. Sci Total Environ 690:1&#x2013;6. 10.1016/j.scitotenv.2019.06.480.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.scitotenv.2019.06.480</ArticleId><ArticleId IdType="pubmed">31299565</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebomah KE, Okoh AI. 2020. Detection of carbapenem-resistance genes in Klebsiella species recovered from selected environmental niches in the Eastern Cape Province, South Africa. Antibiotics 9:425&#x2013;412. 10.3390/antibiotics9070425.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antibiotics9070425</ArticleId><ArticleId IdType="pmc">PMC7400071</ArticleId><ArticleId IdType="pubmed">32708057</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbon MJ, Couto N, David S, Barden R, Standerwick R, Jagadeesan K, Birkwood H, Dulyayangkul P, Avison MB, Kannan A, Kibbey D, Craft T, Habib S, Thorpe HA, Corander J, Kasprzyk-Hordern B, Feil EJ. 2021. A high prevalence of bla OXA-48 in Klebsiella (Raoultella) ornithinolytica and related species in hospital wastewater in South West England. Microb Genom 7:mgen000509. 10.1099/mgen.0.000509.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/mgen.0.000509</ArticleId><ArticleId IdType="pmc">PMC8190614</ArticleId><ArticleId IdType="pubmed">33416467</ArticleId></ArticleIdList></Reference><Reference><Citation>Teban-Man A, Szekeres E, Fang P, Kl&#xfc;mper U, Hegedus A, Baricz A, Berendonk TU, P&#xe2;rvu M, Coman C. 2022. Municipal wastewaters carry important carbapenemase genes independent of hospital input and can mirror clinical resistance patterns. Microbiol Spectr 10:e02711-21. 10.1128/spectrum.02711-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/spectrum.02711-21</ArticleId><ArticleId IdType="pmc">PMC8941857</ArticleId><ArticleId IdType="pubmed">35234513</ArticleId></ArticleIdList></Reference><Reference><Citation>Puljko A, Milakovi&#x107; M, Kri&#x17e;anovi&#x107; S, Kosi&#x107;-Vuk&#x161;i&#x107; J, Babi&#x107; I, Petri&#x107; I, Maravi&#x107; A, Jeli&#x107; M, Udikovi&#x107;-Koli&#x107; N. 2022. Prevalence of enteric opportunistic pathogens and extended-spectrum cephalosporin- and carbapenem-resistant coliforms and genes in wastewater from municipal wastewater treatment plants in Croatia. J Hazard Mater 427:128155. 10.1016/j.jhazmat.2021.128155.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhazmat.2021.128155</ArticleId><ArticleId IdType="pubmed">34991006</ArticleId></ArticleIdList></Reference><Reference><Citation>Galarde-L&#xf3;pez M, Velazquez-Meza ME, Bobadilla-Del-Valle M, Carrillo-Quiroz BA, Cornejo-Ju&#xe1;rez P, Ponce-De-Le&#xf3;n A, Sasso&#xe9;-Gonz&#xe1;lez A, Alpuche-Aranda CM. 2022. Surveillance of antimicrobial resistance in hospital wastewater: identification of carbapenemase-producing Klebsiella spp. Antibiotics 11:288. 10.3390/antibiotics11030288.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antibiotics11030288</ArticleId><ArticleId IdType="pmc">PMC8944648</ArticleId><ArticleId IdType="pubmed">35326752</ArticleId></ArticleIdList></Reference><Reference><Citation>Tac&#xe3;o M, Silva I, Henriques I. 2017. Culture-independent methods reveal high diversity of OXA-48-like genes in water environments. J Water Health 15:519&#x2013;525. 10.2166/wh.2017.260.</Citation><ArticleIdList><ArticleId IdType="doi">10.2166/wh.2017.260</ArticleId><ArticleId IdType="pubmed">28771149</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmiedel J, Falgenhauer L, Domann E, Bauerfeind R, Prenger-Berninghoff E, Imirzalioglu C, Chakraborty T. 2014. Multiresistant extended-spectrum &#x3b2;-lactamase-producing Enterobacteriaceae from humans, companion animals and horses in central Hesse, Germany. BMC Microbiol 14:187. 10.1186/1471-2180-14-187.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2180-14-187</ArticleId><ArticleId IdType="pmc">PMC4105247</ArticleId><ArticleId IdType="pubmed">25014994</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Thungrat K, Boothe DM. 2016. Occurrence of OXA-48 carbapenemase and other &#x3b2;-lactamase genes in ESBL-producing multidrug resistant Escherichia coli from dogs and cats in the United States, 2009&#x2013;2013. Front Microbiol 7:1057. 10.3389/fmicb.2016.01057.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2016.01057</ArticleId><ArticleId IdType="pmc">PMC4939299</ArticleId><ArticleId IdType="pubmed">27462301</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulss S, Stolle I, Stamm I, Leidner U, Heydel C, Semmler T, Prenger-Berninghoff E, Ewers C. 2018. Multispecies and clonal dissemination of OXA-48 carbapenemase in Enterobacteriaceae from companion animals in Germany, 2009&#x2013;2016. Front Microbiol 9:1265. 10.3389/fmicb.2018.01265.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2018.01265</ArticleId><ArticleId IdType="pmc">PMC6010547</ArticleId><ArticleId IdType="pubmed">29963026</ArticleId></ArticleIdList></Reference><Reference><Citation>Stolle I, Prenger-Berninghoff E, Stamm I, Scheufen S, Hassdenteufel E, Guenther S, Bethe A, Pfeifer Y, Ewers C. 2013. Emergence of OXA-48 carbapenemase-producing Escherichia coli and Klebsiella pneumoniae in dogs. J Antimicrob Chemother 68:2802&#x2013;2808. 10.1093/jac/dkt259.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkt259</ArticleId><ArticleId IdType="pubmed">23833179</ArticleId></ArticleIdList></Reference><Reference><Citation>Yousfi M, Touati A, Mairi A, Brasme L, Gharout-Sait A, Guillard T, De Champs C. 2016. Emergence of carbapenemase-producing Escherichia coli isolated from companion animals in Algeria. Microb Drug Resist 22:342&#x2013;346. 10.1089/mdr.2015.0196.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/mdr.2015.0196</ArticleId><ArticleId IdType="pubmed">26741510</ArticleId></ArticleIdList></Reference><Reference><Citation>Loucif L, Gacemi-Kirane D, Cherak Z, Chamlal N, Grainat N, Rolain JM. 2016. First report of German cockroaches (Blattella germanica) as reservoirs of CTX-M-15 extended-spectrum-&#x3b2;-lactamase- and OXA-48 carbapenemase-producing Enterobacteriaceae in Batna University Hospital, Algeria. Antimicrob Agents Chemother 60:6377&#x2013;6380. 10.1128/AAC.00871-16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00871-16</ArticleId><ArticleId IdType="pmc">PMC5038264</ArticleId><ArticleId IdType="pubmed">27458214</ArticleId></ArticleIdList></Reference><Reference><Citation>Melo LC, Boisson MNG, Saras E, M&#xe9;daille C, Boulouis HJ, Madec JY, Haenni M. 2017. OXA-48-producing ST372 Escherichia coli in a French dog. J Antimicrob Chemother 72:1256&#x2013;1258. 10.1093/jac/dkw531.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkw531</ArticleId><ArticleId IdType="pubmed">28039279</ArticleId></ArticleIdList></Reference><Reference><Citation>Yousfi M, Touati A, Muggeo A, Mira B, Asma B, Brasme L, Guillard T, de Champs C. 2018. Clonal dissemination of OXA-48-producing Enterobacter cloacae isolates from companion animals in Algeria. J Glob Antimicrob Resist 12:187&#x2013;191. 10.1016/j.jgar.2017.10.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jgar.2017.10.007</ArticleId><ArticleId IdType="pubmed">29042339</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassan B, Ijaz M, Khan A, Sands K, Serfas GI, Clayfield L, El-Bouseary MM, Lai G, Portal E, Khan A, Watkins WJ, Parkhill J, Walsh TR. 2021. A role for arthropods as vectors of multidrug-resistant Enterobacterales in surgical site infections from South Asia. Nat Microbiol 6:1259&#x2013;1270. 10.1038/s41564-021-00965-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-021-00965-1</ArticleId><ArticleId IdType="pubmed">34580444</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Bayssari C, Olaitan AO, Dabboussi F, Hamze M, Rolain JM. 2015. Emergence of OXA-48-producing Escherichia coli clone ST38 in fowl. Antimicrob Agents Chemother 59:745&#x2013;746. 10.1128/AAC.03552-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.03552-14</ArticleId><ArticleId IdType="pmc">PMC4291434</ArticleId><ArticleId IdType="pubmed">25348536</ArticleId></ArticleIdList></Reference><Reference><Citation>Zurfluh K, Poirel L, Nordmann P, Klumpp J, Stephan R. 2015. First detection of Klebsiella variicola producing OXA-181 carbapenemase in fresh vegetable imported from Asia to Switzerland. Antimicrob Resist Infect Control 4:38. 10.1186/s13756-015-0080-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13756-015-0080-5</ArticleId><ArticleId IdType="pmc">PMC4596300</ArticleId><ArticleId IdType="pubmed">26448862</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhuang Z, Lv L, Lu J, Lin J, Liu JH. 2019. Emergence of Klebsiella pneumoniae and Enterobacter cloacae producing OXA-48 carbapenemases from retail meats in China, 2018. J Antimicrob Chemother 74:3632&#x2013;3634. 10.1093/jac/dkz394.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkz394</ArticleId><ArticleId IdType="pubmed">31730159</ArticleId></ArticleIdList></Reference><Reference><Citation>Irrgang A, Pauly N, Tenhagen BA, Grobbel M, Kaesbohrer A, Hammerl JA. 2020. Spill-over from public health? First detection of an OXA-48-producing Escherichia coli in a German pig farm. Microorganisms 8:855. 10.3390/microorganisms8060855.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms8060855</ArticleId><ArticleId IdType="pmc">PMC7356166</ArticleId><ArticleId IdType="pubmed">32517147</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>